

University of Groningen

Down & Alzheimer

Dekker, Alain Daniel

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2017

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Dekker, A. D. (2017). *Down & Alzheimer: Behavioural biomarkers of a forced marriage*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



7

Ageing Rather Than Aneuploidy Affects Monoamine Neurotransmitters in Brain Regions of Down Syndrome Mouse Models

Alain D. Dekker^{a,b,c} – Yannick Vermeiren^{a,b} – Christelle Albac^c
Eva Lana-Elola^d – Sheona Watson-Scales^d – Dorota Gibbins^d – Tony Aerts^b
Debby Van Dam^{a,b} – Elizabeth M. C. Fisher^e – Victor L. J. Tybulewicz^{d,f}
Marie-Claude Potier^c and Peter P. De Deyn^{a,b}

^a University of Groningen and University Medical Center Groningen

^b Institute Born-Bunge, University of Antwerp

^c Sorbonne Universités UPMC, Institut du Cerveau et de la Moelle épinière, Paris

^d The Francis Crick Institute, London

^e University College London

^f Imperial College London

Published in
Neurobiology of Disease (Elsevier), 2017, 105: 235-244

Abstract

Altered concentrations of monoamine neurotransmitters and metabolites have been repeatedly found in people with Down syndrome (DS, trisomy 21). Because of the limited availability of human post-mortem tissue, DS mouse models are of great interest to study these changes and the underlying neurobiological mechanisms. Although previous studies have shown the potential of Ts65Dn mice – the most widely used mouse model of DS – to model noradrenergic changes, a comprehensive monoaminergic characterization in multiple brain regions has not been performed so far. Here, we used RP-HPLC with electrochemical detection to quantify (nor)adrenergic (NA, adrenaline and MHPG), dopaminergic (DA, HVA and DOPAC), and serotonergic compounds (tryptophan, 5-HT and 5-HIAA) in ten regionally dissected brain regions of Ts65Dn mice, as well as in Dp1Tyb mice – a novel DS mouse model. Comparing young adult aneuploid mice (2.5-5.5 months) with their euploid WT littermates did not reveal generalized monoaminergic dysregulation, indicating that the genetic overload in these mice barely affected the absolute concentrations at this age. Moreover, we studied the effect of ageing in Ts65Dn mice: comparing aged animals (12-13 months) with their younger counterparts revealed a large number of significant changes. In general, the (nor)adrenergic system appeared to be reduced, while serotonergic compounds were increased with ageing. Dopaminergic alterations were less consistent. These overall patterns appeared to be relatively similar for Ts65Dn and WT mice, though more observed changes were regarded significant for WT mice. Similar human post-mortem studies are necessary to validate the monoaminergic construct validity of the Ts65Dn and Dp1Tyb mouse models.

7.1. Introduction

Down syndrome (DS), caused by an additional copy of chromosome 21 (HSA21), is the most common intellectual disability with a genetic origin affecting nearly six million people worldwide (Ballard et al., 2016). DS is generally characterized by behavioural alterations (Dekker et al., 2015b) and reduced cognitive capacities, in particular impaired verbal short-term memory, explicit long-term memory, morphosyntax and an average IQ of 45 (Lott and Dierssen, 2010; Vicari et al., 2004). Moreover, people with DS are at an extremely high risk to develop dementia: 68-80% develop Alzheimer's disease (AD) by the age of 65 years (Wiseman et al., 2015), compared to 11% in the general (non-intellectually disabled) population of 65 years and older (Alzheimer's Association, 2016).

Elucidating the underlying neurobiological mechanisms affecting behaviour and cognition in DS would greatly contribute to understanding the pathophysiology, as well as facilitate development of novel disease-modifying strategies. Of particular interest in this population are monoamine neurotransmitters: noradrenaline (NA), adrenaline, dopamine (DA) and serotonin (5-HT) and their metabolites (summarized in Figure 7.1). A series of neurochemical studies has shown significant alterations in one or more monoamines in various brain regions (Godridge et al., 1987; Reynolds and Godridge, 1985; Risser et al., 1997; Whittle et al., 2007; Yates et al., 1981), cerebrospinal fluid (CSF) (Kay et al., 1987; Schapiro et al., 1987) and serum/plasma (Coppus et al., 2007; Dekker et al., 2015a) of DS individuals as compared to non-DS controls.

Although monoaminergic alterations in CSF and serum/plasma likely reflect changes in the brain, direct analysis of brain tissue is warranted to understand central neurotransmission alterations. Indeed, we previously studied monoamines and metabolites in post-mortem brain regions of behaviourally characterized patients in the general population with (early-onset) AD (Vermeiren et al., 2016, 2015, 2014a, 2014b), frontotemporal dementia (Vermeiren et al., 2016) and dementia with Lewy bodies (Vermeiren et al., 2015). Surprisingly, despite the high risk for dementia in DS, only a few post-mortem studies dating back to the 1980s have investigated monoamines in DS. Unfortunately, post-mortem brain samples from clinically and pathologically well-documented DS individuals have been rarely included in biobanks around the world, severely limiting the possibilities for such research.

Thus, valid mouse models of DS are of great interest to study the potential monoaminergic alterations related to trisomy 21. In addition to the differences between DS and non-DS controls, monoaminergic changes have been reported in DS mouse models, in particular noradrenergic alterations (Dierssen et al., 1997; Lockrow et al., 2011; Salehi et al., 2009). These findings have been primarily observed in Ts(17¹⁶)65Dn mice (Ts65Dn in short), the most widely used and best characterized DS model. HSA21 contains 233 protein-encoding genes: among those genes with a homologue in mice, the majority (~58%) is found on a large segment of mouse chromosome 16 (Mmu16), and to a lesser extent on shorter segments of Mmu10 and Mmu17 (Lana-Elola et al., 2016). Ts65Dn mice carry an additional mini-chromosome that is formed by the translocation of a duplicated segment of Mmu16 to a small part of Mmu17 (Davisson et al., 1990), making them trisomic for approximately 50% of the genes homologous to HSA21, but also for 60 non-homologous genes on Mmu17 (Duchon et al., 2011).




Figure 7.1: Schematic biosynthesis routes of monoamine neurotransmitters and their main metabolites. 5-HT is derived from the amino acid tryptophan, whereas DA (and thus NA and adrenaline) are derived from the amino acid tyrosine. The molecular structures are provided for the compounds that are quantified in this study through reversed-phase high-performance liquid chromatography (RP-HPLC) analyses.

Of profound interest is the significant loss of neurons in the locus coeruleus (LC), the key production site of NA in the pons, in Ts65Dn mice of 12 months of age but not in Ts65Dn mice at 4 months of age as compared to age-matched euploid wildtype (WT_{Ts65Dn}) littermates (Fortress et al., 2015; Lockrow et al., 2011). Neurodegeneration with progressive ageing was further demonstrated by the significant loss of axonal processes and shrinkage of the noradrenergic neurons between 4 and 12 months in Ts65Dn, but not in WT_{Ts65Dn} (Lockrow et al., 2011). Similarly, Salehi and colleagues found a reduced number of LC neurons in Ts65Dn mice at 6 months and 18 months of age, but not in those of 3 months of age, as compared to age-matched WT_{Ts65Dn} mice. Moreover, NA levels in the hippocampus were significantly lower in Ts65Dn than in WT_{Ts65Dn} at 18 months. Despite the pronounced LC degeneration, impaired NA-modulated contextual learning could be rescued in these mice after treatment with the noradrenergic prodrug L-threo-3,4-dihydroxyphenylserine (L-DOPS) or the β 1-adrenergic receptor partial agonist xamoterol (Salehi et al., 2009). Restoration of impaired noradrenergic neurotransmission may thus serve as potential disease-modifying therapy in DS (Phillips et al., 2016).

Despite a large number of studies using Ts65Dn mice, a comprehensive monoaminergic characterization of the brain of this mouse model has not been conducted so far. Therefore, this study aimed to investigate the potential of DS mouse models (construct validity) in modelling the monoaminergic changes in DS by (1) establishing the monoaminergic profile in ten regionally dissected brain regions of aneuploid Ts65Dn mice in comparison to their euploid WT_{Ts65Dn} littermates, and (2) studying the effect of ageing in Ts65Dn and WT_{Ts65Dn} mice. Using an optimized reversed-phase high-performance liquid chromatography (RP-HPLC) set-up with electrochemical detection we detected and quantified (nor)adrenaline and the metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG), DA with its metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC), tryptophan, and 5-HT with its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in each of these brain regions.

Whereas Ts65Dn mice have proven very useful for studying various phenotypic features present in people with DS (Gardiner, 2015), the additional 60 genes from Mmu17 that are not homologous to HSA21 may complicate the interpretation of generated data (Duchon et al., 2011). Therefore, new mouse models have been developed that are only trisomic for genes homologous to HSA21, such as the Dp(16)1Yey strain that is trisomic for the entire homologous segment on Mmu16 (Yu et al., 2010). Similar to Dp(16)1Yey, the Dp1Tyb mouse model has been generated to exclude the effect of the irrelevant Mmu17 genes triplicated in Ts65Dn. Using Cre/loxP-mediated recombination, Dp1Tyb mice were engineered with a triplication of Mmu16 genes from *Lipi* to *Zbtb21* including 148 protein-encoding Mmu16 genes (Lana-Elola et al., 2016). Given the debate on the non-homologous genes in Ts65Dn mice, we also performed a first exploratory analysis of the monoaminergic profile of this new Dp1Typ mouse model.

7.2. Materials & Methods

Animals

As Ts65Dn is the most widely used DS mouse model, the aim of this project was to establish its monoaminergic profile and evaluate the effect of ageing in this model. Since

Ts65Dn are trisomic for 60 Mmu17 genes that are not homologous to HSA21, we also conducted a first (pilot) study with young Dp1Tyb mice, which resemble the human situation more closely from a genetic point of view. Given the time-intensive nature of this project, the availability of aged Ts65Dn mice and that the aforementioned studies in Ts65Dn implicated monoaminergic changes with ageing, possibly resembling the changes in humans, we studied the effect of ageing only in the Ts65Dn mouse model.

Table 7.1: Overview of experimental groups

Experimental groups	N mice	Age in days
Ts65Dn-young	21	117 (91-174)
WT _{Ts65Dn} -young	18	118.5 (110-174)
Ts65Dn-aged	11	377 (354-399)
WT _{Ts65Dn} -aged	10	382 (376-382)
Dp1Tyb	9	82 (79-93)
WT _{Dp1Tyb}	9	84 (79-93)

Age in days is provided as median with the age range between brackets.

Ts65Dn mice

Male Ts65Dn (n=32) and euploid WT_{Ts65Dn} littermates (n=28) were bred, aged and sacrificed in the Institut du Cerveau et de la Moelle Epinière (ICM, Paris, France). To study the effect of ageing, we considered two age ranges (Table 7.1): young adult animals (~3-5.5 months) and aged animals (~12-13 months). Since the original homozygous Ts65Dn mice suffer from blindness due to the recessive retinal degeneration 1 mutation Pde6b^{rd1}, we used an alternative strain that is wild-type for Pde6b^{rd1} (The Jackson Laboratory, Bar Harbor, USA, stock number 005252), thus preventing retinal degeneration. The Ts65Dn colony was maintained by crossing trisomic Ts65Dn females (B6EiC3Sn.BLiA-Ts(17¹⁶)65Dn/DnJ) to B6EiC3Sn.Bli males (The Jackson Laboratory, stock numbers 005252 and 003647, respectively). Mixed-genotype groups were housed under standard conditions with ad libitum food and water, constant room temperature and a 12h light/dark cycle. The experiments were compliant with the ethical standards and animal welfare regulations of the French Ministry of Agriculture and the EU Directive 2010/63/EU. MC Potier has the authorization for experiments on vertebrates (N°A-75-2138, Direction Départementale de la Protection des Populations de Paris, Service Protection et Santé Animales, Environnement).

Dp1Tyb mice

The engineering of the C57BL/6J.129P2-Dp(16Lipi-Zbtb21)1TybEmcf/Nimr (Dp1Tyb) strain is described in Lana-Elola et al. (2016). In this first exploratory analysis of this model, we used young male Dp1Tyb (n=9) mice and euploid WT_{Dp1Tyb} littermates (n=9) aged 2.5-3 months (Table 7.1). All mice had been backcrossed at least 5 generations onto the C57BL/6J background. The animals were bred, aged and sacrificed in the Francis Crick Institute (London, UK). Animals were housed in specific pathogen free conditions, with *ad libitum* food and water, constant room temperature and a 12h light/dark cycle. The characterization and breeding of Dp1Tyb mice was carried out under a Project License granted by the UK Home Office, and in accordance with the EU Directive 2010/63/EU.

Sacrifice

After intraperitoneal anesthesia with pentobarbital, mice were sacrificed by cervical dislocation and subsequently fully submersed in liquid nitrogen (3 minutes) to stop metabolization of monoamines. Mice were stored at -80°C and shipped on dry ice to the Laboratory of Neurochemistry and Behaviour in Antwerp for further processing.

Regional brain dissection

Brains were extracted from the frozen mice using surgical tools, and subsequently micro-dissected on a cold plate under a binocular microscope, resembling a previously published protocol (Van Dam et al., 2005). Per mouse, ten (sub)cortical brain regions were obtained: frontal cortex, temporal cortex, parietal cortex, occipital cortex, hippocampus, striatum, (hypo)thalamus, brainstem, cerebellum and olfactory bulb. The weight of the brain samples was determined in pre-weighted Eppendorf tubes. Samples were kept at -80°C until RP-HPLC analyses.

Sample preparation

Brain samples were defrosted to 4°C and subsequently homogenized in 800 µl sample buffer (50 mM citric acid, 50 mM phosphoric acid, 0.1 mM EDTA, 8 mM KCl and 1.8 mM octane-1-sulfonic acid sodium salt (OSA), adjusted to pH=3.6) using a Bio-Gen PRO200 homogenizer (PRO Scientific Inc., Oxford, CT, USA). Thereupon, 450 µl homogenate was transferred onto a 3000 Da Amicon® Ultra 0.5 Centrifugal Filter (Millipore, Ireland) that had been pre-washed (2x) using 450 µl sample buffer (centrifugation: 14000 x *g*, 25 min, 4°C). The Amicon® filter loaded with homogenate was centrifuged (14000 x *g*, 40 min, 4°C). Per region per mouse, 5 µl of the resulting filtrate was simultaneously injected by an Alexys™ AS 100 automatic sample injector onto two parallel ALF-125 columns.

RP-HPLC

Noradrenergic (NA, adrenalin and MHPG), dopaminergic (DA, DOPAC and HVA) and serotonergic compounds (TRP, 5-HT and 5-HIAA) were simultaneously quantified in one run using an optimized RP-HPLC set-up with ion-pairing (OSA) and amperometric electrochemical detection, as published before (Dekker et al., 2015a; Van Dam et al., 2014). In summary, we used an Alexys™ Dual Monoamines Analyzer (Antec Leyden BV, Zoeterwoude, The Netherlands), including two LC 110 pumps for a constant flow rate (40 µl/min), two parallel microbore ALF-125 columns (250 mm x 1 mm, 3 µm particle size, 36°C) with a porous C₁₈ silica stationary phase for separation of the compounds and two Decade II electrochemical amperometric detectors with VT03 electrochemical flow cells containing an In Situ Ag/AgCl reference electrode (ISAAC) at 670 mV and a 0.7 mm glassy carbon working electrode. RP-HPLC runs were conducted per brain region and compounds were analysed in duplicate (output ranges resp. 1 nA and 500 pA). The mobile phase consisted of the aforementioned sample buffer with 13% methanol as organic modifier. Dihydroxybenzylamine hydrochloride (DHBA) and 5-hydroxy-N-methyl tryptamine oxalate (5-HMT) were used as internal standards. Chromatograph analyses were performed with Clarity™ software (DataApex Ltd., Prague, Czech Republic).

Statistics

Histograms and Shapiro-Wilk tests ($P < 0.05$) demonstrated that the monoamines and metabolites did not have a normal distribution overall. Accordingly, non-parametric tests were selected: Mann Whitney U tests were used to compare all monoaminergic data between Dp1Tyb and WT_{Dp1Tyb} littermates, whereas Kruskal-Wallis with post-hoc Mann Whitney U tests were applied to compare the young Ts65Dn, young WT_{Ts65Dn}, aged Ts65Dn and aged WT_{Ts65Dn} groups. To account for multiple comparisons we corrected the P-values using the Benjamini-Hochberg procedure with a False Discovery Rate of 0.05 given the exploratory and hypothesis-generating nature of this study. Only the corrected P-values smaller than 0.05 (i.e. regarded significant) are reported in Tables 7.2-7.4. Statistical analyses were performed using IBM SPSS Statistics version 23.0 and Microsoft Office Excel 2010.

7.3. Results

Each monoaminergic compound was detected and quantified in all ten brain regions. Based on these concentrations, five accompanying ratios were calculated: MHPG:NA (reflecting noradrenergic metabolism), DOPAC:DA and HVA:DA (reflecting dopaminergic catabolism), 5-HIAA:5-HT (reflecting serotonergic catabolism) and, finally, HVA:5-HIAA (indicating the effect of serotonergic inhibition on dopaminergic neurotransmission). In the supplementary material (S1-S6), the concentrations and ratios for each brain region are provided per experimental group (median and quartiles, including the number of samples in which a specific compound was detected). All compounds and ratios were compared between young Ts65Dn vs. young WT_{Ts65Dn} (Table 7.2), aged Ts65Dn vs. aged WT_{Ts65Dn} (Table 7.3), aged Ts65Dn vs. young Ts65Dn (Table 7.4), aged WT_{Ts65Dn} vs. young WT_{Ts65Dn} (Table 7.5), and young Dp1Tyb vs. young WT_{Dp1Tyb} mice. Since the Ts65Dn and Dp1Tyb mouse models have different genetic backgrounds and were bred and housed in two different institutes, these DS models are not compared with each other, but only to their age-matched WT littermates (same background, same conditions). Significant P-values of the individual group comparisons are provided in Tables 7.2–7.4.

Effect of aneuploidy

Ts65Dn vs. WT_{Ts65Dn} mice

To determine the effect of the aneuploidy on the monoamine neurotransmitters and their metabolites, we compared Ts65Dn mice with their WT_{Ts65Dn} littermates. First of all, we compared the young animals (Table 7.2): MHPG and the accompanying MHPG:NA ratio in the olfactory bulb were significantly higher in young Ts65Dn than in young WT_{Ts65Dn} mice. No other significant changes in the (nor)adrenergic system were found. Concerning the dopaminergic system, DA and DOPAC were significantly lower in the (hypo)thalamus of Ts65Dn compared to WT_{Ts65Dn} mice, but not in other regions. With respect to the serotonergic compounds, decreased levels were observed for 5-HIAA and 5-HT in the hippocampus, and 5-HIAA in the occipital cortex of young Ts65Dn compared to young WT_{Ts65Dn} mice.

Secondly, we compared the aged Ts65Dn mice with their aged WT_{Ts65Dn} littermates (Table 7.3). Apart from a significant reduction of MHPG in the frontal cortex of

Ts65Dn mice, no other significant changes were observed for the (nor)adrenergic system in any of the brain regions. Although DA, DOPAC and HVA did not differ significantly between the groups, the subsequent ratios turned out to be significantly altered: the DOPAC:DA ratio was lower in the frontal cortex, parietal cortex, and cerebellum of Ts65Dn mice (indicating reduced DA catabolism), while the ratio HVA:DA in the temporal cortex was increased (indicating increased DA metabolization) in aged Ts65Dn compared to aged WT_{Ts65Dn} mice. No differences were found in the serotonergic system.

Young Dp1Tyb vs. young WT_{Dp1Tyb} mice

In addition to the Ts65Dn mouse model, we also assessed the monoaminergic profile of young Dp1Tyb mice in comparison with their WT_{Dp1Tyb} littermates: only the NA concentration in the occipital cortex was significantly increased in Dp1Tyb mice compared to WT_{Dp1Tyb} ($P=0.047$), while none of the other monoamines, metabolites or ratios were significantly altered between both groups.

Effect of ageing

Aged Ts65Dn vs. young Ts65Dn mice

To study the effect of ageing in Ts65Dn mice, we compared two age groups: Table 7.4 depicts the significant differences between aged Ts65Dn (~12-13 months) and their younger counterparts (~3-5.5 months). To start with the noradrenergic system, NA concentrations only differed in the striatum, but not in other regions. Adrenaline, in contrast, was substantially affected by ageing: significantly lower levels were found in the frontal cortex, parietal cortex, hippocampus and (hypo)thalamus, and higher levels in the temporal cortex. Similarly, MHPG was reduced in the frontal and parietal cortex, but was elevated in the olfactory bulb. Consequently, the ratio MHPG:NA in the parietal cortex and the striatum was decreased in aged compared to young Ts65Dn mice. Overall, adrenaline, MHPG and the MHPG:NA ratio were predominantly reduced with ageing.

In contrast to these results, the changes in the dopaminergic system are less consistent: DA was increased in the temporal cortex, but decreased in the striatum of aged vs. young Ts65Dn mice. DOPAC was significantly higher in the temporal cortex and cerebellum, while lower HVA concentrations were found in the hippocampus and striatum. The resulting DOPAC:DA and HVA:DA ratios were not altered for the different brain regions, apart from an increased DOPAC:DA ratio in the cerebellum and a decreased HVA:DA ratio in the temporal cortex.

Concerning the serotonergic system, 5-HIAA and the 5-HIAA:5-HT ratio were increased in the temporal and parietal cortex, pointing at increased serotonergic turnover. In the striatum, 5-HT was increased and the ratio 5-HIAA:5-HT reduced, indicating reduced serotonergic catabolism. Finally, the inhibitory effect of the serotonergic system on the dopaminergic system is reflected by the HVA:5-HIAA ratio, which turned out to be significantly lower in the striatum and the (hypo)thalamus of aged Ts65Dn mice compared to their younger counterparts.

Table 7.2: young Ts65Dn vs. young WT_{Ts65Dn} mice (aneuploidy effect)

	(nor)adrenergic system				dopaminergic system				serotonergic system				
	NA	A	MHPG	MHPG: NA	DA	DOPAC	HVA	DOPAC: DA	HVA: DA	TRP	5-HT	5-HIAA	5-HIAA: 5-HT
Frontal cortex	-	-	-	-	-	-	-	-	-	-	-	-	-
Temporal cortex	-	-	-	-	-	-	-	-	-	-	-	-	-
Parietal cortex	-	-	-	-	-	-	-	-	-	-	-	-	-
Occipital cortex	-	-	-	-	-	-	-	-	-	-	-	-	-
Hippocampus	-	-	-	-	-	-	-	-	-	-	-	-	-
Striatum	-	-	-	-	-	-	-	-	-	-	-	-	-
(Hypo)thalamus	-	-	-	-	↓ 0.044	↓ 0.024	-	-	-	-	-	-	-
Brainstem	-	-	-	-	-	-	-	-	-	-	-	-	-
Cerebellum	-	-	-	-	-	-	-	-	-	-	-	-	-
Olfactory bulb	-	-	↑ 0.015	↑ 0.040	-	-	-	-	-	-	-	-	-
Summary	-	-	↑	↑	↓	↓	-	-	-	-	↓	↓ ↓	-

Table 7.3: aged Ts65Dn vs. aged WT_{Ts65Dn} mice (aneuploidy effect)

	(nor)adrenergic system				dopaminergic system				serotonergic system					
	NA	A	MHPG	MHPG: NA	DA	DOPAC	HVA	DOPAC: DA	HVA: DA	TRP	5-HT	5-HIAA	5-HIAA: 5-HT	HVA: 5-HIAA
Frontal cortex	-		↓ 0.023	-	-	-	-	↓ 0.022		-	-	-	-	-
Temporal cortex	-	n.d.		-	-	-	-		↑ 0.043	-	-	-	-	-
Parietal cortex	-	-	-	-	-	-	-	↓ 0.035		-	-	-	-	-
Occipital cortex	-	-	-	-	-	-	-		-	-	-	-	-	-
Hippocampus	-	-	-	-	-	-	-		-	-	-	-	-	-
Striatum	-	-	-	-	-	-	-		-	-	-	-	-	-
(Hypo)thalamus	-	-	-	-	-	-	-		-	-	-	-	-	-
Brainstem	-	-	-	-	-	-	-		-	-	-	-	-	-
Cerebellum	-	-	-	-	-	-	-	↓ 0.034		-	-	-	-	-
Olfactory bulb	-	-	-	-	-	-	-		-	-	-	-	-	-
Summary	-	-	↓	-	-	-	-	↓ ↓ ↓	↑	-	-	-	-	-

Red boxes indicate a significant increase, and green boxes depict a significant decrease for a compound or ratio in young Ts65Dn vs. young WT_{Ts65Dn} mice (Table 7.2) and aged Ts65Dn vs. aged WT_{Ts65Dn} mice (Table 7.3). The summary row indicates the consequent overall increase (red) or decrease (green). 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3-4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline; n.d., not detectable.

Table 7.4: aged Ts65Dn vs. young Ts65Dn mice (ageing effect)

	(nor)adrenergic system				dopaminergic system				serotonergic system				
	NA	A	MHPG	MHPG: NA	DA	DOPAC	HVA	DOPAC: DA	HVA: DA	TRP	5-HT	5-HIAA	5-HIAA: 5-HT
Frontal cortex	-	↓ 0.017	↓ 0.031	-	-	-	-	-	-	-	-	-	-
Temporal cortex	-	↑ 0.003	-	-	↑ 0.012	↑ 0.035	-	-	↓ 0.005	-	-	↑ 0.000	↑ 0.003
Parietal cortex	-	↓ 0.029	↓ 0.002	↓ 0.001	-	-	-	-	-	-	-	↑ 0.004	↑ 0.047
Occipital cortex	-	-	-	-	-	-	-	-	-	-	-	-	-
Hippocampus	-	↓ 0.039	-	-	-	-	↓ 0.043	-	-	-	-	-	-
Striatum	↑ 0.004	-	-	↓ 0.019	↓ 0.020	-	↓ 0.001	-	-	-	↑ 0.005	-	↓ 0.015
(Hypo)thalamus	-	↓ 0.039	-	-	-	-	-	-	-	-	-	-	↓ 0.007
Brainstem	-	-	-	-	-	-	-	-	-	-	-	-	↓ 0.012
Cerebellum	-	-	-	-	-	↑ 0.000	-	↑ 0.000	-	-	-	-	-
Olfactory bulb	-	-	↑ 0.019	-	-	-	-	-	-	-	-	-	-
Summary	↑	↓ ↓ ↓ ↓	↓ ↓ ↑	↓ ↓	↓ ↑	↑ ↑	↓ ↓	↑	↓	-	↑	↑ ↑	↓ ↑ ↑

Table 7.5: aged WT_{Ts65Dn} vs. young WT_{Ts65Dn} mice (ageing effect)

	(nor)adrenergic system				dopaminergic system				serotonergic system				
	NA	A	MHPG	MHPG: NA	DA	DOPAC	HVA	DOPAC: DA	HVA: DA	TRP	5-HT	5-HIAA	5-HIAA: 5-HT
Frontal cortex	-	↓ 0.000	-	-	-	-	-	-	-	-	-	↑ 0.009	↑ 0.000
Temporal cortex	-	n.d.	↑ 0.013	↑ 0.030	↑ 0.013	-	-	↓ 0.013	↓ 0.000	↑ 0.000	-	-	↓ 0.000
Parietal cortex	-	↓ 0.000	↓ 0.000	↓ 0.000	-	-	-	↑ 0.011	-	-	-	↑ 0.008	-
Occipital cortex	-	↓ 0.000	↓ 0.001	↓ 0.000	-	-	↓ 0.010	-	↓ 0.001	-	-	-	↓ 0.010
Hippocampus	-	-	-	-	-	-	-	-	↓ 0.030	-	-	-	-
Striatum	↑ 0.014	-	-	↓ 0.007	↓ 0.004	↓ 0.045	↓ 0.003	-	-	-	↑ 0.001	-	↓ 0.002
(Hypo)thalamus	-	↓ 0.001	-	-	-	-	↓ 0.002	-	-	-	-	-	↓ 0.005
Brainstem	-	-	↑ 0.007	↑ 0.001	-	-	-	-	-	-	-	-	↓ 0.000
Cerebellum	-	-	-	-	-	↑ 0.000	-	↑ 0.000	↑ 0.017	-	-	↑ 0.001	-
Olfactory bulb	-	-	↑ 0.000	↑ 0.000	-	↑ 0.047	-	↑ 0.012	-	↑ 0.000	-	-	-
Summary	↑	↓ ↓ ↓ ↓	↓ ↓	↑ ↑ ↑	↓ ↑	↓ ↑ ↑	↓ ↓ ↓	↑ ↑ ↑	↓ ↓ ↓	↑ ↑	↑	↑ ↑ ↑	↓ ↓ ↓

Red boxes indicate a significant increase, and green boxes depict a significant decrease for a compound or ratio in aged Ts65Dn vs. young Ts65Dn mice (Table 7.4) and aged WT_{Ts65Dn} vs. young WT_{Ts65Dn} mice (Table 7.5). The summary row indicates the consequent overall increase (red) or decrease (green). The yellow boxes indicate that the direction of the change differed between the different regions: the arrows illustrate whether the direction of change is ex aequo (e.g. ↓ ↑) or inclines towards an increase (e.g. ↓ ↓ ↑) or decrease (e.g. ↓ ↓ ↓). 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline; n.d., not detectable

Aged WT_{Ts65Dn} vs. young WT_{Ts65Dn} mice

To evaluate whether the observed changes in aged Ts65Dn vs. young Ts65Dn mice are specific for this model, i.e. relate to the triplicated genes or to ageing in general, we also compared aged WT_{Ts65Dn} mice (~12-13 months) vs. young (~3-5.5 months) animals (Table 7.5). In the (nor)adrenergic system, striatal NA concentrations were higher in aged than in young WT_{Ts65Dn} mice, resembling the observed increase in the striatum of Ts65Dn mice. Furthermore, adrenaline was lower in the frontal cortex, parietal cortex, occipital cortex and (hypo)thalamus of aged WT_{Ts65Dn} mice than in their younger counterparts, which again (largely) resembles the aforementioned findings in the Ts65Dn model. In the aged animals, MHPG levels were significantly reduced in cortical regions (parietal and occipital cortex), but increased in brainstem and olfactory bulb. Accordingly, the ratio MHPG:NA decreased in parietal and occipital cortex, as well as in the striatum, and increased in the temporal cortex, brainstem and olfactory bulb.

In accordance with the Ts65Dn results, DA levels were significantly higher in the temporal cortex and lower in the striatum of aged vs. young WT_{Ts65Dn} mice. DOPAC and HVA were both decreased in the striatum as well. In addition, aged WT_{Ts65Dn} animals showed increased DOPAC levels in the cerebellum and olfactory bulb, and reduced HVA concentrations in the occipital cortex and (hypo)thalamus, compared to their younger counterparts. Concerning the ratios, DOPAC:DA was predominantly increased (parietal cortex, cerebellum and olfactory bulb, but decreased in temporal cortex), while the ratio HVA:DA was mainly decreased (temporal cortex, occipital cortex and hippocampus, but increased in cerebellum).

Finally, an overall increase of serotonergic compounds became apparent when comparing aged vs. young WT_{Ts65Dn} mice. Significant increases were found for tryptophan in the temporal cortex and olfactory bulb, 5-HT in the striatum, 5-HIAA in the frontal cortex, temporal cortex and cerebellum and the ratio 5-HIAA:5-HT in the frontal cortex and parietal cortex. In contrast, the ratio 5-HIAA:5-HT was decreased in the striatum. As in Ts65Dn mice, the ratio HVA:5-HIAA was generally reduced in aged WT_{Ts65Dn} mice, indicating enhanced serotonergic inhibition on the dopaminergic system.

7.4. Discussion

Using a previously optimized and validated RP-HPLC methodology (Van Dam et al., 2014), we detected noradrenergic (NA, adrenaline and MHPG), dopaminergic (DA, DOPAC and HVA) and serotonergic (TRP, 5-HT and 5-HIAA) compounds in ten regionally dissected brain regions to establish the monoaminergic profiles of Dp1Tyb and Ts65Dn mice and their WT littermates. First of all, we studied the effect of aneuploidy in both models. Comparing young Dp1Tyb with young WT_{Dp1Tyb} showed that only occipital NA levels differed significantly, suggesting that the additional genes in Dp1Tyb mice hardly affected monoamine concentrations at this age. Similarly, Tables 7.2 and 7.3 depict the comparisons between Ts65Dn mice and WT_{Ts65Dn} littermates, and do not show generalized monoaminergic dysregulation either, even though a few more changes were regarded significant than in the Dp1Tyb mouse model. Accordingly, the genetic overload in these DS mouse models barely affected the absolute monoaminergic concentrations at the analysed ages. Secondly, we studied the effect of ageing within Ts65Dn and WT_{Ts65Dn} mice

comparing aged (~12-13 months) vs. young animals (~3-5.5 months). The overall patterns of monoaminergic alterations appeared to be relatively similar in both genotypes, though more observed changes (especially in the ratios) were regarded significant for WT_{Ts65Dn} mice. Indeed, these overall patterns, rather than the individual concentration changes in a specific region, are most relevant in this exploratory study. In the next section, the main patterns and changes will be highlighted and discussed.

Noradrenergic system

The LC, located in the pons near the fourth ventricle, is the major source of NA in the brain. The ascending noradrenergic neurons originating from this small nucleus project to an extensive number of (sub)cortical brain regions, including the frontal cortex, hippocampus, striatum, (hypo)thalamus, cerebellum and olfactory bulb, mediating, among others, arousal, attention and contextual memory. Importantly, LC neurons are the sole source of NA for the cortex, hippocampus, cerebellum and most of the thalamus (Aston-Jones and Cohen, 2005; Trillo et al., 2013; Vermeiren et al., 2016). A loss of LC neurons may thus especially affect these brain areas.

Previously, such a loss was reported in Ts65Dn mice of 6, 12 and 18 months but not in younger Ts65Dn mice (aged 3 and 4 months) compared to age-matched WT_{Ts65Dn} mice (Fortress et al., 2015; Lockrow et al., 2011; Salehi et al., 2009). Here, we did not observe significant NA concentration changes between Ts65Dn and WT_{Ts65Dn} in both age groups for the brainstem (including LC) or any of the noradrenergic projection regions (Tables 7.2 and 7.3). Indeed, immunohistochemical characterization of the catecholaminergic nuclei (anti-tyrosine hydroxylase antibodies) previously showed intense staining of the LC in both Ts65Dn and control mice (3 months) without evident differences between both groups, indicating that the additional genes in Ts65Dn did not influence the early LC development (Megías et al., 1997). This is further supported by human findings: NA levels were not significantly altered in the frontal cortex of fetal DS tissue (20 weeks) as compared to age-matched non-DS fetuses (Whittle et al., 2007). Similarly, the genetic overload in Dp1Tyb mice does not appear to affect NA levels other than an increase in the occipital cortex in comparison with WT_{Dp1Tyb} mice – that is the only significant difference in all compounds and regions in this strain. Next, comparing trisomic mice with their WT littermates revealed no significant changes in adrenaline, whereas MHPG was only altered in the olfactory bulb of young Ts65Dn vs. WT_{Ts65Dn} and frontal cortex of aged Ts65Dn vs. WT_{Ts65Dn} mice. The latter resembles the reduced levels of MHPG, which freely diffuses over the blood-brain barrier, in serum of elderly DS individuals as compared to non-DS controls (Dekker et al., 2015a), and may relate to the previously reported deficits in (pre)frontal cortex-mediated spatial working memory in Ts65Dn mice aged 9-12 months (Dudchenko, 2004; Faizi et al., 2011; Yoon et al., 2008). Nevertheless, it appears that the aneuploidy had a very limited effect on the (nor)adrenergic system.

In contrast, the effect of ageing (i.e. comparing aged vs. young animals of the same genotype) is pronounced for adrenaline and MHPG, but not for NA. We did not find age-related NA alterations other than the increased NA levels in the striatum (Tables 7.4 and 7.5). Interestingly, the precursor of NA, that is DA, was decreased in the striatum of the aged mice, possibly pointing at an increased turnover of DA into NA (Tables 7.4 and

7.5). The virtually unaltered NA levels between the young and aged animals possibly relate to enhanced NA synthesis in the remaining noradrenergic cells, i.e. a compensatory mechanism (Schapiro et al., 1987). With progressive neuronal loss in the LC during ageing (Fortress et al., 2015; Lockrow et al., 2011; Salehi et al., 2009), which is also observed in DS (Mann et al., 1987b; Marcyniuk et al., 1988), the increasingly smaller number of remaining cells will not be able to keep noradrenergic neurotransmission at level, causing NA concentrations to start decreasing from a certain moment onwards. Indeed, Salehi et al. found an age-related decrease in hippocampal NA concentrations, which was only significant for Ts65Dn vs. WT_{Ts65Dn} at 18 months. Interestingly, immunostaining for the β 1-adrenergic receptor, present on postsynaptic targets of LC neurons in the hippocampus, revealed an increased size (at 3 and 6 months) and number (at 6 months) of immune-reactive cells in Ts65Dn mice compared with age-matched WT_{Ts65Dn} mice, pointing at a postsynaptic compensation for the age-related decrease in NA levels (Salehi et al., 2009). This may resemble the human situation, where significantly reduced NA levels have been reported later in life in several (sub)cortical post-mortem brain samples of elderly DS individuals presenting AD neuropathology as compared to controls (Godridge et al., 1987; Reynolds and Godridge, 1985; Risser et al., 1997; Yates et al., 1981).

Conversely, adrenaline levels appear to be substantially altered over time in both Ts65Dn and WT_{Ts65Dn} mice. A relatively similar pattern was observed for both genotypes: older animals had significantly decreased adrenaline levels in cortical regions and (hypo)thalamus (Tables 7.4 and 7.5). Hippocampal adrenaline was also reduced in aged Ts65Dn. Adrenaline is formed by methylation of NA by the rate-limiting enzyme phenylethanolamine N-methyltransferase (PNMT, Figure 7.1). The reduced adrenaline levels are not likely due to reduced NA levels, given the fact that NA levels were unaltered. Instead, lower adrenaline levels may be due to a decrease in the amount or activity of PNMT enzyme. Burke and co-workers, for instance, described a strong reduction of enzymatic activity due to lower amounts of PNMT enzymes in human AD brain tissue as compared to controls (Burke et al., 1987). Since the current study methodology did not enable enzymatic measurements (the small tissue samples were entirely used for RP-HPLC analyses), future studies need to elucidate whether PNMT plays a role in the adrenergic changes in these mice.

MHPG levels were also affected by ageing: reduced adrenaline levels in the frontal and parietal cortex of aged Ts65Dn mice, and parietal and occipital cortex of aged WT_{Ts65Dn} mice likely resulted in the decreased MHPG levels in these regions. Whereas MHPG and the MHPG:NA ratio generally decreased with ageing in Ts65Dn, the pattern for WT_{Ts65Dn} mice was more diffuse. NA and adrenaline are converted into MHPG through the enzymes monoamine oxidase (MAO, Figure 7.1) and catechol-O-methyltransferase (COMT, Figure 7.1). Previously, MAO activity in platelets of DS individuals was found to be reduced (Benson and Southgate, 1971; Fowler et al., 1981) or unaltered (Lott et al., 1972), whereas COMT activity was higher (Gustavson et al., 1973) or unaltered (Brahe et al., 1985) in DS erythrocytes. The COMT enzyme is a methyl transferase, using the methyl group of S-adenosylmethionine (SAM). The levels of the methyl donor SAM are reduced in DS (Dekker et al., 2014), suggesting that COMT activity might be reduced in DS as well.

Nevertheless, it remains to be elucidated whether the amount or activity of MAO and COMT change over time in these mice.

Taken together, the (nor)adrenergic system was not substantially affected by the aneuploidy in Ts65Dn or Dp1Tyb mice. However, ageing revealed strong alterations in multiple brain regions. Since LC degeneration and altered (nor)adrenergic neurotransmission are implicated in DS and AD, others have studied the effect of (nor)adrenergic agonists in (aged) Ts65Dn mice as potential therapeutic strategies (Phillips et al., 2016). Faizi and colleagues, for instance, reported reproducible learning and memory deficits in Ts65Dn mice of 9-12 months of age that could be restored by administering the β 1-adrenergic receptor partial agonist xamoterol, thus suggesting that such cognitive deficits are (in part) mediated by the (nor)adrenergic system (Faizi et al., 2011). Similarly, xamoterol and the NA-prodrug L-DOPS reversed contextual learning impairment in 6-month-old Ts65Dn mice (Salehi et al., 2009). Moreover, the long-acting β 2-adrenergic receptor agonist formoterol significantly improved cognitive capacities, synaptic density and complexity of the dendritic tree of new dentate granule cells in the hippocampus of Ts65Dn mice (5-6 months) (Dang et al., 2014). More recently, Fortress and colleagues demonstrated LC degeneration in 12-month-old Ts65Dn mice, and found that selective stimulation of the remaining noradrenergic LC neurons using designer receptors exclusively activated by designer drugs (DREADDs) restored memory function (Fortress et al., 2015).

In the context of the high risk for AD in DS, it is important to note that the amyloid precursor protein (APP) gene located on HSA21 is also triplicated in Ts65Dn mice, but that the APP cleavage product amyloid-beta ($A\beta$) does not accumulate into plaques in Ts65Dn mice like in the human condition (Gardiner, 2015; Reeves et al., 1995). Consequently, Ts65Dn is primarily a model of the developmental trisomy 21-related deficits in DS and can be used to study the effect of *APP* overexpression, but not $A\beta$ accumulation, with ageing. Interestingly, Salehi and colleagues found that the loss of LC neurons was eliminated by deleting the third copy of the *APP* gene in Ts65Dn mice, thus indicating that triplicated *APP* plays an essential role in LC degeneration (Salehi et al., 2009). Indeed, a comparable cell loss of approximately 60% was found in post-mortem LC samples from elderly DS (57-59 years) and AD patients (61-82 years) in the general population compared to healthy controls (60-76 years) (German et al., 1992). Importantly, in both AD and older DS samples, neuronal loss mainly affected the neurons projecting to the cortex, while the non-cortical projecting cells were spared (German et al., 1992; Marcyniuk et al., 1988). Similarly, LC neuronal loss in Ts65Dn mice at 12 months was mainly restricted to the rostral neurons projecting to the forebrain and hippocampus, while the caudal regions were spared (Lockrow et al., 2011). That might explain the discrepancy between our finding of decreased cortical MHPG levels and the increased MHPG concentrations in the brainstem with ageing. Cautious interpretation of the results is warranted in relation to findings in aged post-mortem DS samples: virtually all DS individuals have omnipresent AD-pathology (i.e. $A\beta$ plaques and tau tangles) in their brain from the age of 40 years onwards (Mann, 1988), complicating the comparison between findings in DS and Ts65Dn mice that do not model human AD neuropathology in DS.

Interestingly, LC degeneration does not only affect noradrenergic neurotransmission, but also impacts cholinergic signaling (Lockrow et al., 2011). Basal forebrain cholinergic neurons innervate the amygdala, hippocampus and neocortex and are strongly implicated in attention and memory processes. A significant loss of cholinergic cells has been found in AD and DS (Casanova et al., 1985; Mann et al., 1985; Mufson et al., 2003) and in Ts65Dn mice by 12 months of age (Cooper et al., 2001). LC degeneration in Ts65Dn mice appears to precede the onset of cholinergic degeneration (Phillips et al., 2016). Indeed, Lockrow and colleagues demonstrated that neurotoxin-induced NA depletion resulted in accelerated cholinergic degeneration in Ts65Dn mice, but not in WT_{Ts65Dn} mice. Learning and memory deficits were aggravated in Ts65Dn mice as well (Lockrow et al., 2011). In the current study, we report an overall decrease of adrenaline, MHPG and the MHPG:NA ratio with ageing in Ts65Dn mice, which may possibly contribute to cholinergic pathology in this mouse model. Future studies should consider studying monoaminergic alterations in relation to cholinergic deficits.

In conclusion, the (nor)adrenergic system was mainly affected by ageing rather than by aneuploidy. Comparing aged vs. young animals revealed altered patterns across multiple brain regions. In particular, adrenaline and MHPG differed in most cortical regions as well as in a few subcortical structures. In Ts65Dn an overall decrease of adrenaline, MHPG and the MHPG:NA ratio became apparent with ageing. In WT_{Ts65Dn} mice, adrenaline decreased with ageing as well, while the directions of change for MHPG and MHPG:NA were less straightforward.

Dopaminergic system

DA, derived from L-tyrosine (Figure 7.1), is mainly produced by the substantia nigra (SN) and ventral tegmental area (VTA) located in the mesencephalon. The SN primarily projects to the striatum (hence referred to as the nigrostriatal pathway), whereas the VTA projects to the limbic (mesolimbic pathway) and cortical areas (mesocortical pathway). DA is involved in regulating motor activity, emotions, reward and has been associated with cognition (Lanari et al., 2006; Nieoullon, 2002; Trillo et al., 2013).

Studying the effect of aneuploidy on the dopaminergic system showed that the levels of DA, DOPAC and HVA are virtually unaltered, apart from decreased DA and DOPAC levels in the (hypo)thalamus of young Ts65Dn vs. WT_{Ts65Dn} mice. Indeed, immunohistochemical staining of the dopaminergic neurons (anti-tyrosine hydroxylase antibodies) in the SN and VTA of 3-month-old Ts65Dn mice and WT_{Ts65Dn} mice revealed similar reaction intensities in both genotypes. The unaltered morphology and number of reactive cells between Ts65Dn and WT_{Ts65Dn} led the authors to conclude that the triplicated genes in Ts65Dn do not affect the development of dopaminergic nuclei (Megías et al., 1997). In young Ts65Dn mice, we found reduced DA levels in the (hypo)thalamus. In the human situation, levels of DA and the DA receptor 1-containing complex were significantly lower in the frontal cortex of DS fetuses than in age-matched control fetuses (Keihan Falsafi et al., 2016; Whittle et al., 2007). Furthermore, the lack of significant alterations between the older Ts65Dn and WT_{Ts65Dn} mice resembles the lack of significant changes in multiple post-mortem brain samples of DS individuals vs. controls (Godridge et al., 1987).

In contrast to the relatively consistent age-related patterns of change in the (nor)adrenergic and serotonergic systems, the results for the dopaminergic system are less consistent over the months for the different compounds/regions. In the human situation, Mann and colleagues reported neuronal loss in the VTA, but not in the SN of aged DS (51-65 years) and AD patients (53-89 years) (Mann et al., 1987a). Indeed, comparison of older and younger DS samples revealed no significant cell loss or reduced nucleolar volume in the SN over time (Mann et al., 1987b). In Ts65Dn mice of 3 months, neuronal loss was absent (Megías et al., 1997), but whether this is true for aged Ts65Dn mice remains unclear. With ageing, this study showed that DA increased in the temporal cortex, but decreased in the striatum for aged vs. young Ts65Dn mice, as well as for aged vs. young WT_{Ts65Dn} mice. In mice, striatal neurons receive input from both the SN and VTA (Zeiss, 2005). The finding that DOPAC is increased in various regions, while HVA is decreased may relate to changes in MAO or COMT activity (Figure 7.1). COMT transfers a methyl group of SAM to DOPAC (3-O-methylation) resulting in HVA (Meiser et al., 2013). As described before, the levels of the methyl donor SAM are reduced in DS (Dekker et al., 2014), possibly affecting DOPAC methylation and thus HVA levels.

In short, the dopaminergic system was barely affected by the triplicated HSA21-homologous genes in Ts65Dn or Dp1Tyb mice compared to their WT littermates. Ageing resulted in altered DA, DOPAC and HVA levels, but further studies are required to mechanistically demonstrate the cause of these alterations.

Serotonergic system

The indolamine 5-HT, derived from L-tryptophan (Figure 7.1), is produced in various cell groups in the medulla, pons and mesencephalon. The majority of ascending serotonergic neurons arise from the dorsal and median raphe nuclei. In particular, the dorsal raphe nuclei project to the cortex and striatum, while the median raphe nuclei target the cortex, hippocampus and hypothalamus (Trillo et al., 2013). The main role of the serotonergic system is (behavioural) inhibition, and regulation of mood and aggression, for instance (Lanctôt et al., 2001).

Here, we did not find widespread serotonergic changes between Ts65Dn and WT_{Ts65Dn} mice. This is in accordance with the conclusion of Megías et al. that the development of the serotonergic system is not evidently influenced by the triplicated genes in Ts65Dn mice. Indeed, their immunohistochemical results demonstrated a similar distribution of serotonin-immunoreactive cells (anti-serotonin antibodies) in the medial and dorsal raphe nuclei of Ts65Dn and WT_{Ts65Dn} mice at 3 months of age (Megías et al., 1997). 5-HT has been implicated in the impaired hippocampal neurogenesis and dendritic hypotrophy in Ts65Dn mice. Ts65Dn mice, similar to DS individuals, have a smaller hippocampus indeed. Prenatal and neonatal treatment with the selective serotonin reuptake inhibitor fluoxetine was found to normalize hippocampal neurogenesis and restore dendritic architecture, hippocampal cellularity and memory functions, even 1.5-3 months after treatment cessation (reviewed in: Stagni et al., 2015). Although we do not see many serotonergic changes between both genotypes, we did find significantly reduced 5-HT and 5-HIAA levels in the hippocampus of young Ts65Dn compared to young WT_{Ts65Dn} mice.

Whether these findings reflect the human situation remains unclear due to a lack of (post-mortem) studies in young DS individuals. Reduced 5-HT and 5-HIAA levels have, indeed, been reported in post-mortem DS hippocampus samples (Godridge et al., 1987; Reynolds and Godridge, 1985). Other studies confirmed the pattern of lower 5-HT and 5-HIAA concentrations in DS (Risser et al., 1997; Seidl et al., 1999; Whittle et al., 2007; Yates et al., 1986). These human post-mortem studies were mainly performed on samples of elderly DS individuals presenting AD neuropathology. For instance, Yates et al. studied six DS brains over 50 years of age with numerous plaques and tangles in the cortex and reported significantly decreased 5-HT levels in amygdala, caudate nucleus (part of striatum) and cingulate cortex, but no such change was found in a 27-year-old DS case without AD pathology (Yates et al., 1986). Considering fetal samples, however, Whittle et al. found reduced 5-HT and 5-HIAA in the frontal cortex of fetal DS tissue as compared to age-matched control aborted fetuses (Whittle et al., 2007), suggesting that this reduction is not related to the AD pathology, but to the trisomy 21 itself. To which extent the murine findings thus resemble the human situation is questionable given the fact that A β does not accumulate into plaques in these mice, and comparison of aged Ts65Dn with aged WT_{Ts65Dn} did not yield significant alterations in any serotonergic compound or region.

Studying the effect of ageing within each genotype revealed a more pronounced pattern: an overall increase of serotonergic compounds with ageing. This is in remarkable contrast with the aforementioned reduced serotonergic levels in the elderly DS brain samples. Indeed, comparison of older DS brains (with AD pathology) with young DS brains (without/minimal AD pathology) revealed a significant decrease in the number of cells and the nucleolar volume with ageing (Mann et al., 1987b). Neuronal loss has been reported in the dorsal tegmental nucleus of the raphe nuclei in six DS patients over 50 years, as well as in AD patients in the general population (Mann et al., 1985). The activity of the tryptophan hydroxylase enzyme (Figure 7.1), key to 5-HT biosynthesis, is reduced in AD as well (Trillo et al., 2013), but whether this is also true for DS and Ts65Dn is unclear. The link between AD pathology and 5-HT levels is further supported by the finding that the increased levels of APP-derived β CTF peptide could be normalized in adult Ts65Dn mice through fluoxetine treatment (Stagni et al., 2015). Therefore, the underlying mechanism of serotonergic increase with ageing in these mice should be studied more extensively.

Future implications

Cautious interpretation of the results is required, because the underlying causes for (the lack of) monoaminergic alterations remain to be elucidated. The virtually unaltered NA levels and the likely presence of a compensatory mechanism, for instance, illustrate the necessity to study monoaminergic alterations over a longer period of time. Therefore, we propose that future studies should evaluate mice in a larger number of age groups, for instance at 3, 6, 9, 12, 15, 18 and 21 months. Immunohistochemical staining of (nor)adrenergic, dopaminergic and serotonergic neurons, and measurements of the amount and activity of key enzymes like PNMT, MAO and COMT (Figure 7.1) in mice of different ages would be a valuable addition to understand the age-related changes. Despite the fact that the age ranges of the young Ts65Dn and Dp1Tyb mice in the current study slightly overlapped, the young Ts65Dn mice were, on average, a few weeks older

than the Dp1Tyb mice. Although it was not the aim to compare both models with each other (different genetic backgrounds and different institutes), it could be considered a limitation of this study. Comparative age-matched studies should certainly be considered in the future, providing that the mice are bred and housed at the same location. Moreover, the novel Dp1Tyb mouse model has not been fully characterized yet. Dp1Tyb mice present congenital heart defects comparable to DS (Lana-Elola et al., 2016). Brain morphology and behavioural deficits have not been reported so far, although brain development and cognitive deficits in Dp1Tyb mice are expected to resemble those reported in the essentially similar Dp(16)1Yey mouse model (Goodliffe et al., 2016; Yu et al., 2010). Future studies should specifically evaluate the behavioural phenotype (DS-related deficits) of Dp1Tyb mice in young, adult and aged life.

Currently, it is complex to evaluate the monoaminergic construct validity of the mouse models in comparison with the human situation, because of the lack of comprehensive post-mortem brain studies in DS. The few available monoaminergic studies were conducted twenty to forty years ago and have various methodological limitations, including (1) long post-mortem delays (PMD), (2) small sample sizes, and (3) absence of DS brains free of extensive AD pathology. First, long PMDs over 30 hours, for instance, were not unusual (Godridge et al., 1987; Risser et al., 1997). Indeed, PMD is a confounding factor since it may affect the (regional) concentrations of specific monoamines and metabolites (Kontur et al., 1994; Van Dam et al., 2014). Therefore, we have submersed the mice in liquid nitrogen within minutes to stop further monoaminergic turnover. Secondly, (very) small sample sizes were used, ranging from 2 to 8 individuals (Godridge et al., 1987; Reynolds and Godridge, 1985; Risser et al., 1997; Yates et al., 1981), thus complicating the generalizability of the human results. Thirdly, mainly older DS brains with virtually omnipresent AD-like neuropathology were studied (Mann, 1988), making it rather complex to disentangle the effects of AD pathology, normal ageing, and trisomy 21. To establish whether the monoaminergic phenotypes of DS mouse models reflect alterations in the human situation, we should study post-mortem human brain samples in greater detail, and thus prioritize the collection of these samples through, for instance, multicenter brain bank initiatives. In short, monoamine neurotransmitter systems have not been comprehensively studied in the human DS situation, illustrating the need to be careful with drawing conclusions at this stage about the monoaminergic construct validity of Ts65Dn and Dp1Tyb mouse models.

With respect to the high risk for AD in DS, the scientific community is in great need of animal models that integrate DS and AD phenotypes, i.e. a model for the neurodevelopmental deficits in DS (such as Ts65Dn) that also develops AD pathology and related neurodegeneration over time. Clearly, overexpression of wild-type *APP* is not sufficient for the development of vast AD neuropathology in these mice (Wiseman et al., 2015). Indeed, we studied the effect of triplicated genes, including *APP*, as well as the effect of normal ageing in these mice that model DS, but not AD. Novel rodent models for AD in DS are being developed, but these are not available yet. Such models would be of great value to study monoaminergic changes due to 'pathologic' ageing.

7.5. Conclusion

To the best of our knowledge, this study is the first to comprehensively quantify monoamine neurotransmitters and metabolites in ten regionally dissected brain regions in two DS mouse models in comparison with their WT littermates. Monoaminergic concentrations were barely altered by the aneuploidy in young adult Ts65Dn and Dp1Tyb mice compared with their WT littermates. Ageing to 12-13 months, however, revealed strong alterations in the monoaminergic compounds in multiple brain regions in both Ts65Dn and WT mice. Future studies should focus on replicating these age-related monoaminergic alterations and elucidate the underlying causes. Post-mortem studies with human DS brain samples are necessary to validate the monoaminergic construct validity of the Ts65Dn and Dp1Tyb mouse models of DS.

References

- Alzheimer's Association, 2016. 2016 Alzheimer's disease facts and figures. *Alzheimer's Dement.* 12, 459–509.
- Aston-Jones, G., Cohen, J.D., 2005. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. *Annu. Rev. Neurosci.* 28, 403–50.
- Ballard, C., Mobley, W.C., Hardy, J., Williams, G., Corbett, A., 2016. Dementia in Down's syndrome. *Lancet Neurol.* 15, 622–636.
- Benson, P.F., Southgate, J., 1971. Diminished activity of platelet monoamine oxidase in Down's syndrome. *Am. J. Hum. Genet.* 23, 211–214.
- Brahe, C., Serra, A., Morton, N.E., Opitz, J.M., Reynolds, J.F., 1985. Erythrocyte catechol-O-methyltransferase activity: Genetic analysis in nuclear families with one child affected by down syndrome. *Am. J. Med. Genet.* 21, 373–384.
- Burke, W.J., Chung, H.D., Nakra, B.R.S., Grossberg, G.T., Joh, T.H., 1987. Phenylethanolamine N-methyltransferase activity is decreased in Alzheimer's disease brains. *Ann. Neurol.* 22, 278–280.
- Casanova, M.F., Walker, L.C., Whitehouse, P.J., Price, D.L., 1985. Abnormalities of the nucleus basalis in Down's syndrome. *Ann. Neurol.* 18, 310–313.
- Cooper, J.D., Salehi, A., Delcroix, J.-D., Howe, C.L., Belichenko, P. V., Chua-Couzens, J., Kilbridge, J.F., Carlson, E.J., Epstein, C.J., Mobley, W.C., 2001. Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion. *Proc. Natl. Acad. Sci.* 98, 10439–10444.
- Coppus, A.M.W., Fekkes, D., Verhoeven, W.M., Tuinier, S., Egger, J.I., van Duijn, C.M., 2007. Plasma amino acids and neopterin in healthy persons with Down's syndrome. *J. Neural Transm.* 114, 1041–1045.
- Dang, V., Medina, B., Das, D., Moghadam, S., Martin, K.J., Lin, B., Naik, P., Patel, D., Noshery, R., Wesson Ashford, J., Salehi, A., 2014. Formoterol, a Long-Acting β_2 Adrenergic Agonist, Improves Cognitive Function and Promotes Dendritic Complexity in a Mouse Model of Down Syndrome. *Biol. Psychiatry* 75, 179–188.
- Davisson, M.T., Schmidt, C., Akeson, E.C., 1990. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. *Prog. Clin. Biol. Res.* 360, 263–280.
- Dekker, A.D., Coppus, A.M.W., Vermeiren, Y., Aerts, T., van Duijn, C.M., Kremer, B.P., Naudé, P.J.W., Van Dam, D., De Deyn, P.P., 2015a. Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome. *J. Alzheimer's Dis.* 43, 871–891.
- Dekker, A.D., De Deyn, P.P., Rots, M.G., 2014. Epigenetics: The neglected key to minimize learning and memory deficits in Down syndrome. *Neurosci. Biobehav. Rev.* 45C, 72–84.
- Dekker, A.D., Strydom, A., Coppus, A.M.W., Nizetic, D., Vermeiren, Y., Naudé, P.J.W., Van Dam, D., Potier, M.-C., Fortea, J., De Deyn, P.P., 2015b. Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease? *Cortex* 73, 36–61.
- Dierssen, M., Vallina, I.F., Baamonde, C., Garcia-Calatayud, S., Lumberras, M.A., Florez, J., 1997. Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome. *Brain Res.* 749, 238–244.
- Duchon, A., Raveau, M., Chevalier, C., Nalesso, V., Sharp, A.J., Herault, Y., 2011. Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. *Mamm. genome* 22, 674–684.
- Dudchenko, P.A., 2004. An overview of the tasks used to test working memory in rodents. *Neurosci. Biobehav. Rev.* 28, 699–709.
- Faizi, M., Bader, P.L., Tun, C., Encarnacion, A., Kleschevnikov, A.M., Belichenko, P. V., Saw, N., Priestley, M., Tsien, R.W., Mobley, W.C., Shamloo, M., 2011. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. *Neurobiol. Dis.* 43, 397–413.
- Fortress, A.M., Hamlett, E.D., Vazey, E.M., Aston-Jones, G., Cass, W.A., Boger, H.A., Granholm, A.C., 2015. Designer receptors enhance memory in a mouse model of Down syndrome. *J. Neurosci.* 35, 1343–53.
- Fowler, C.J., Wiberg, A., Gustavson, K.H., Winblad, B., 1981. Platelet monoamine oxidase activity in Down's syndrome. *Clin. Genet.* 19, 307–311.
- Gardiner, K.J., 2015. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations. *Drug Des. Devel. Ther.* 9, 103–25.
- German, D.C., Manaye, K.F., White, C.L., Woodward, D.J., McIntire, D.D., Smith, W.K., Kalaria, R.N., Mann, D.M., 1992. Disease-specific patterns of locus coeruleus cell loss. *Ann. Neurol.* 32, 667–76.

- Godridge, H., Reynolds, G.P., Czudek, C., Calcutt, N.A., Benton, M., 1987. Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. *J. Neurol. Neurosurg. Psychiatry* 50, 775–778.
- Goodliffe, J.W., Olmos-Serrano, J.L., Aziz, N.M., Pennings, J.L.A., Guedj, F., Bianchi, D.W., Haydar, T.F., 2016. Absence of Prenatal Forebrain Defects in the Dp(16)1Yey/+ Mouse Model of Down Syndrome. *J. Neurosci.* 36, 2926–2944.
- Gustavson, K.H., Wetterberg, L., Backstrom, M., Ross, S.B., 1973. Catechol-O-methyltransferase activity in erythrocytes in Down's syndrome. *Clin. Genet.* 4, 279–280.
- Kay, A.D., Schapiro, M.B., Riker, A.K., Haxby, J. V., Rapoport, S.I., Cutler, N.R., 1987. Cerebrospinal fluid monoaminergic metabolites are elevated in adults with Down's syndrome. *Ann. Neurol.* 21, 408–411.
- Keihan Falsafi, S., Dierssen, M., Ghafari, M., Pollak, A., Lubec, G., 2016. Reduced cortical neurotransmitter receptor complex levels in fetal Down syndrome brain. *Amino Acids* 48, 103–116.
- Kontur, P.J., Al-Tikriti, M., Innis, R.B., Roth, R.H., 1994. Postmortem stability of monoamines, their metabolites, and receptor binding in rat brain regions. *J. Neurochem.* 62, 282–90.
- Lana-Elola, E., Watson-Scales, S.D., Slender, A., Gibbins, D., Martineau, A., Douglas, C., Mohun, T., Fisher, E.M., Tybulewicz, V.L.J., 2016. Genetic dissection of Down syndrome-associated congenital heart defects using a new mouse mapping panel. *Elife* 5, 1–20.
- Lanari, A., Amenta, F., Silvestrelli, G., Tomassoni, D., Parnetti, L., 2006. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. *Mech. Ageing Dev.* 127, 158–165.
- Lancôt, K.L., Herrmann, N., Mazzotta, P., 2001. Role of serotonin in the behavioral and psychological symptoms of dementia. *J. Neuropsychiatry Clin. Neurosci.* 13, 5–21.
- Lockrow, J., Boger, H., Gerhardt, G., Aston-Jones, G., Bachman, D., Granholm, A.C., 2011. A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. *J. Alzheimer's Dis.* 23, 471–489.
- Lott, I.T., Chase, T.N., Murphy, D.L., 1972. Down's syndrome: transport, storage, and metabolism of serotonin in blood platelets. *Pediatr. Res.* 6, 730–735.
- Lott, I.T., Dierssen, M., 2010. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. *Lancet Neurol.* 9, 623–633.
- Mann, D.M.A., 1988. Alzheimer's disease and Down's syndrome. *Histopathology* 13, 125–37.
- Mann, D.M.A., Yates, P.O., Marcyniuk, B., 1987a. Dopaminergic neurotransmitter systems in Alzheimer's disease and in Down's syndrome at middle age. *J. Neurol. Neurosurg. Psychiatry* 50, 341–344.
- Mann, D.M.A., Yates, P.O., Marcyniuk, B., Ravindra, C.R., 1987b. Loss of neurones from cortical and subcortical areas in Down's syndrome patients at middle age. Quantitative comparisons with younger Down's patients and patients with Alzheimer's disease. *J. Neurol. Sci.* 80, 79–89.
- Mann, D.M.A., Yates, P.O., Marcyniuk, B., Ravindra, C.R., 1985. Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. *J. Ment. Defic. Res.* 29 (Pt 2), 125–135.
- Marcyniuk, B., Mann, D.M.A., Yates, P.O., Ravindra, C.R., 1988. Topography of nerve cell loss from the locus caeruleus in middle aged persons with Down's syndrome. *J. Neurol. Sci.* 83, 15–24.
- Megías, M., Verduga, R., Dierssen, M., Flórez, J., Insausti, R., Crespo, D., 1997. Cholinergic, serotonergic and catecholaminergic neurons are not affected in Ts65Dn mice. *Neuroreport* 8, 3475–8.
- Meiser, J., Weindl, D., Hiller, K., 2013. Complexity of dopamine metabolism. *Cell Commun. Signal.* 11, 34.
- Mufson, E.J., Ginsberg, S.D., Ikonomic, M.D., DeKosky, S.T., 2003. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. *J. Chem. Neuroanat.* 26, 233–42.
- Nieoullon, A., 2002. Dopamine and the regulation of cognition and attention. *Prog. Neurobiol.* 67, 53–83.
- Phillips, C., Fahimi, A., Das, D., Mojabi, F.S., Ponnusamy, R., Salehi, A., 2016. Noradrenergic System in Down Syndrome and Alzheimer's Disease: A Target for Therapy. *Curr. Alzheimer Res.* 68–83.
- Reeves, R.H., Irving, N.G., Moran, T.H., Wohn, A., Kitt, C., Sisodia, S.S., Schmidt, C., Bronson, R.T., Davisson, M.T., 1995. A mouse model for Down syndrome exhibits learning and behaviour deficits. *Nat. Genet.* 11, 177–184.
- Reynolds, G.P., Godridge, H., 1985. Alzheimer-like brain monoamine deficits in adults with Down's syndrome. *Lancet* 2, 1368–1369.
- Risser, D., Lubec, G., Cairns, N., Herrera-Marschitz, M., 1997. Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. *Life Sci.* 60, 1231–1237.
- Salehi, A., Faizi, M., Colas, D., Valletta, J., Laguna, J., Takimoto-Kimura, R., Kleschevnikov, A.M., Wagner, S.L., Aisen, P.S., Shamloo, M., Mobley, W.C., 2009. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. *Sci. Transl. Med.* 1, 7ra17.
- Schapiro, M.B., Kay, A.D., May, C., Ryker, A.K., Haxby, J. V., Kaufman, S., Milstien, S., Rapoport, S.I., 1987. Cerebrospinal fluid monoamines in Down's syndrome adults at different ages. *J. Ment. Defic. Res.* 31 (Pt 3), 259–269.
- Seidl, R., Kaehler, S.T., Prast, H., Singewald, N., Cairns, N., Gratzner, M., Lubec, G., 1999. Serotonin (5-HT) in brains of adult patients with Down syndrome. *J. neural Transm.* 57, 221–232.
- Stagni, F., Giacomini, A., Guidi, S., Ciani, E., Bartesaghi, R., 2015. Timing of therapies for Down syndrome: the sooner, the better. *Front. Behav. Neurosci.* 9, 265.
- Trillo, L., Das, D., Hsieh, W., Medina, B., Moghadam, S., Lin, B., Dang, V., Sanchez, M.M., De Miguel, Z., Ashford, J.W., Salehi, A., 2013. Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care. *Neurosci. Biobehav. Rev.* 37, 1363–1379.
- Van Dam, D., Marescau, B., Engelborghs, S., Cremers, T., Mulder, J., Staufenbiel, M., De Deyn, P.P., 2005. Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. *Neurochem. Int.* 46, 409–422.
- Van Dam, D., Vermeiren, Y., Aerts, T., De Deyn, P.P., 2014. Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic

- amines and metabolites in human brain tissue. *J. Chromatogr.* 1353, 28–39.
- Vermeiren, Y., Janssens, J., Aerts, T., Martin, J.-J., Sieben, A., Van Dam, D., De Deyn, P.P., 2016. Brain serotonergic and noradrenergic deficiencies in behavioral variant frontotemporal dementia compared to early-onset Alzheimer's disease. *J. Alzheimer's Dis.* 53, 1079–1096.
- Vermeiren, Y., Van Dam, D., Aerts, T., Engelborghs, S., De Deyn, P.P., 2014a. Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. *Neurobiol. Aging* 35, 2691–2700.
- Vermeiren, Y., Van Dam, D., Aerts, T., Engelborghs, S., De Deyn, P.P., 2014b. Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. *J. Alzheimer's Dis.* 41, 819–833.
- Vermeiren, Y., Van Dam, D., Aerts, T., Engelborghs, S., Martin, J.-J., De Deyn, P.P., 2015. The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. *Alzheimers. Res. Ther.* 7, 1–18.
- Vicari, S., Bates, E., Caselli, M.C., Pasqualetti, P., Gagliardi, C., Tonucci, F., Volterra, V., 2004. Neuropsychological profile of Italians with Williams syndrome: an example of a dissociation between language and cognition? *J. Int. Neuropsychol. Soc.* 10, 862–866.
- Whittle, N., Sartori, S.B., Dierssen, M., Lubec, G., Singewald, N., 2007. Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. *Pediatrics* 120, e1465–71.
- Wiseman, F.K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V.L.J., Fisher, E.M., Strydom, A., 2015. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. *Nat. Rev. Neurosci.* 16, 564–74.
- Yates, C.M., Ritchie, I.M., Simpson, J., Maloney, A.F., Gordon, A., 1981. Noradrenaline in Alzheimer-type dementia and Down syndrome. *Lancet* 2, 39–40.
- Yates, C.M., Simpson, J., Gordon, A., 1986. Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease. *Neurosci. Lett.* 65, 189–192.
- Yoon, T., Okada, J., Jung, M.W., Kim, J.J., 2008. Prefrontal cortex and hippocampus subserve different components of working memory in rats. *Learn. Mem.* 15, 97–105.
- Yu, T., Liu, C., Belichenko, P. V., Clapcote, S.J., Li, S., Pao, A., Kleschevnikov, A.M., Bechard, A.R., Asrar, S., Chen, R., Fan, N., Zhou, Z., Jia, Z., Chen, C., Roder, J.C., Liu, B., Baldini, A., Mobley, W.C., Yu, Y.E., 2010. Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. *Brain Res.* 1366, 162–71.
- Zeiss, C.J., 2005. Neuroanatomical phenotyping in the mouse: the dopaminergic system. *Vet. Pathol.* 42, 753–73.

Table S1: Young Ts65Dn mice			(nor)adrenergic system				dopaminergic system				serotonergic system					
			NA (ng/ml)	A (ng/ml)	MHPG (ng/ml)	MHPG: NA	DA (ng/ml)	DOPAC (ng/ml)	HVA (ng/ml)	DOPAC: DA	HVA: DA	TRP (ng/ml)	5-HT (ng/ml)	5-HIAA (ng/ml)	5HIAA: 5HT	HVA: 5HIAA
Frontal cortex	25%		377.9	14.8	67.7	0.16	28.8	19.1	48.5	0.34	0.93	3056.4	513.8	111.7	0.20	0.36
	50%		439.5	20.3	85.0	0.18	42.6	22.5	55.9	0.56	1.37	3321.0	546.7	138.6	0.22	0.45
	75%		532.4	26.3	98.2	0.21	73.7	30.8	78.8	0.75	1.82	3671.8	650.4	154.3	0.28	0.54
	N		21	21	21	21	21	21	21	21	21	21	21	21	21	21
Temporal cortex	25%		389.4	3.4	65.8	0.14	36.9	31.4	76.3	0.58	1.43	3091.6	376.7	128.4	0.31	0.55
	50%		446.5	5.4	77.6	0.18	55.5	51.6	108.9	0.83	1.71	3374.6	436.2	157.6	0.34	0.67
	75%		467.5	9.1	92.5	0.20	99.5	72.2	150.3	0.92	2.48	3736.2	493.8	169.6	0.39	0.96
	N		21	20	21	21	21	21	21	21	21	21	21	21	21	21
Parietal cortex	25%		510.2	14.9	83.6	0.17	24.8	8.4	11.3	0.32	0.34	3207.9	278.6	103.5	0.32	0.08
	50%		549.6	21.7	104.2	0.19	30.4	12.7	17.0	0.44	0.56	3659.6	357.4	128.7	0.34	0.14
	75%		603.7	33.8	123.1	0.22	35.5	14.9	24.3	0.51	0.89	4043.5	408.9	139.9	0.39	0.19
	N		21	19	21	21	21	21	21	21	21	21	21	21	21	21
Occipital cortex	25%		330.8	8.3	47.3	0.13	16.8	2.9	6.1	0.11	0.27	3224.9	138.5	96.4	0.51	0.06
	50%		356.3	11.1	55.1	0.15	19.8	6.2	11.4	0.24	0.51	3588.1	169.7	114.5	0.62	0.10
	75%		412.3	14.0	66.9	0.18	26.6	7.6	13.4	0.37	0.74	3923.0	198.4	122.0	0.78	0.12
	N		21	21	21	21	21	20	19	20	19	21	21	21	21	19
Hippocampus	25%		390.9	4.8	35.3	0.09	34.5	15.6	44.9	0.39	0.99	3106.4	466.4	346.9	0.70	0.11
	50%		428.8	6.1	48.7	0.10	42.3	22.3	50.7	0.44	1.11	3492.0	518.4	404.9	0.80	0.12
	75%		468.8	9.9	74.3	0.16	51.7	24.4	54.6	0.55	1.32	4218.8	551.5	454.8	0.85	0.15
	N		21	14	21	21	21	21	21	21	21	21	21	21	21	21
Striatum	25%		96.6	4.0	33.0	0.27	10299.0	936.5	1252.5	0.08	0.10	3064.6	323.7	289.4	0.83	3.91
	50%		115.6	9.8	38.8	0.33	12237.7	1089.2	1413.2	0.09	0.12	3370.9	357.2	303.7	0.87	4.49
	75%		129.4	14.5	54.0	0.45	13311.1	1247.3	1576.5	0.10	0.13	3896.1	383.0	341.3	0.97	4.90
	N		21	16	21	21	21	21	21	21	21	21	21	21	21	21
(Hypo)thalamus	25%		847.0	3.8	76.1	0.08	209.3	104.7	185.2	0.42	0.72	3381.8	605.0	424.7	0.66	0.38
	50%		942.8	8.5	86.1	0.09	253.1	121.5	199.9	0.48	0.81	3670.0	629.5	443.9	0.69	0.45
	75%		1012.9	13.0	95.4	0.11	281.0	138.2	224.8	0.58	1.02	4007.2	666.7	510.1	0.79	0.50
	N		21	21	21	21	21	21	21	21	21	21	21	21	21	21
Brainstem	25%		508.3	3.7	60.5	0.12	36.4	28.5	40.1	0.69	0.98	2518.2	428.7	408.9	0.84	0.09
	50%		575.6	5.5	72.9	0.12	41.2	35.6	50.3	0.75	1.23	2785.6	479.7	470.4	1.01	0.11
	75%		601.8	7.4	82.4	0.14	48.7	38.8	65.2	0.91	1.50	3023.6	520.8	519.4	1.17	0.13
	N		21	17	21	21	21	21	21	21	21	21	21	21	21	21
Cerebellum	25%		264.6	2.3	27.6	0.08	10.8	1.5	7.6	0.11	0.55	3359.2	70.4	80.1	1.01	0.08
	50%		301.2	4.8	29.9	0.10	11.7	3.1	10.3	0.23	0.70	3550.7	90.5	98.6	1.16	0.10
	75%		353.6	7.7	35.9	0.14	18.8	5.5	13.2	0.51	1.09	4177.9	97.3	108.1	1.44	0.12
	N		21	18	21	21	21	21	21	21	21	21	21	21	21	21
Olfactory bulb	25%		246.8	5.3	40.6	0.15	163.3	58.6	127.5	0.36	0.79	3362.8	287.0	121.8	0.38	0.92
	50%		310.3	6.6	49.7	0.16	199.7	79.7	170.7	0.43	0.87	3552.6	323.5	139.7	0.43	1.14
	75%		325.7	7.9	54.0	0.19	225.3	106.7	199.8	0.49	1.00	3882.2	355.2	164.0	0.51	1.49
	N		21	15	21	21	21	21	21	21	21	21	21	21	21	21

Monoamines, metabolites and ratios are expressed as median (50%) with the interquartile range (25%-75%). The number of samples in which a specific compound was detected is provided as well. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline.

Table S2: Young WT _{16SDN} mice			(nor)adrenergic system				dopaminergic system				serotonergic system				
	NA (ng/ml)	A (ng/ml)	MHPG (ng/ml)	MHPG: NA	DA (ng/ml)	DOPAC (ng/ml)	HVA (ng/ml)	DOPAC: HVA	HVA: DA	TRP (ng/ml)	5-HT (ng/ml)	5-HIAA (ng/ml)	5HIAA: 5HT	HVA: 5HIAA	
Frontal cortex	25%	346.8	16.2	74.0	0.16	31.5	20.6	55.9	0.54	1.43	2763.2	541.2	136.9	0.22	0.38
	50%	405.6	24.7	82.5	0.20	35.2	25.1	62.1	0.64	1.66	3317.2	591.9	154.2	0.26	0.42
	75%	511.6	31.0	94.8	0.24	52.0	31.0	71.9	0.84	2.30	4074.8	633.5	161.4	0.28	0.48
	N	18	18	18	18	18	18	18	18	18	18	18	18	18	18
Temporal cortex	25%	379.8	3.8	62.7	0.14	32.6	31.1	74.7	0.61	1.33	3081.5	383.3	151.3	0.32	0.50
	50%	432.1	5.9	75.3	0.18	52.4	40.6	110.0	0.79	1.87	3471.4	474.8	185.0	0.36	0.62
	75%	461.5	8.7	87.5	0.21	111.5	70.5	140.1	1.03	2.64	3850.9	600.3	200.8	0.45	0.76
	N	18	17	18	18	18	18	18	18	18	18	18	18	18	18
Parietal cortex	25%	442.8	21.2	83.1	0.17	27.4	10.3	17.4	0.24	0.40	3131.5	314.2	126.7	0.33	0.12
	50%	502.5	23.4	101.1	0.18	37.1	12.8	21.2	0.38	0.56	3676.1	379.4	148.6	0.40	0.16
	75%	599.6	26.7	114.4	0.21	48.3	15.8	31.1	0.45	0.96	4285.2	443.4	160.7	0.46	0.18
	N	18	18	18	18	18	18	17	17	18	18	18	18	18	17
Occipital cortex	25%	320.1	10.7	46.8	0.13	15.2	3.3	8.1	0.20	0.42	3236.6	165.7	123.0	0.49	0.07
	50%	331.3	12.1	53.0	0.15	19.4	6.2	11.5	0.23	0.64	3584.6	221.0	132.4	0.60	0.09
	75%	389.5	13.9	69.6	0.19	25.5	9.7	15.6	0.44	0.85	3926.8	277.1	142.3	0.76	0.10
	N	18	18	18	18	18	15	17	15	17	18	18	18	18	17
Hippocampus	25%	383.5	5.1	37.9	0.09	37.0	17.4	46.3	0.35	1.02	3162.6	532.1	397.6	0.74	0.09
	50%	460.7	7.1	71.0	0.13	42.8	21.3	52.2	0.48	1.15	3566.9	574.2	473.4	0.80	0.11
	75%	560.3	12.0	81.3	0.17	51.3	27.9	61.6	0.63	1.38	4454.1	683.3	561.3	0.88	0.12
	N	18	13	18	18	18	18	18	18	18	18	18	18	18	18
Striatum	25%	94.4	3.7	36.1	0.25	9842.3	967.6	1191.3	0.09	0.11	2932.3	356.8	303.9	0.76	3.79
	50%	132.6	8.7	43.7	0.32	11849.4	1188.0	1391.1	0.10	0.12	3536.3	387.8	330.2	0.86	4.45
	75%	160.9	13.7	49.6	0.49	14123.5	1370.4	1598.0	0.11	0.12	3997.4	438.5	360.0	0.95	4.76
	N	18	16	18	18	18	18	18	18	18	18	18	18	18	18
(Hypo)thalamus	25%	830.6	8.0	78.0	0.08	231.6	129.6	201.9	0.36	0.52	3529.3	625.2	445.5	0.60	0.41
	50%	960.9	14.8	84.6	0.10	324.4	147.7	232.5	0.44	0.78	3746.7	687.6	459.6	0.66	0.51
	75%	1117.2	19.7	101.8	0.11	402.6	163.0	264.7	0.53	0.89	4100.1	744.5	502.5	0.83	0.55
	N	18	18	18	18	18	18	18	18	18	18	18	18	18	18
Brainstem	25%	504.5	2.6	65.0	0.11	36.9	28.5	40.7	0.72	0.99	2456.8	466.0	390.7	0.80	0.09
	50%	562.0	5.3	66.8	0.12	40.0	35.1	48.5	0.83	1.24	2710.7	504.2	477.4	1.00	0.11
	75%	643.2	7.4	75.9	0.13	47.3	44.1	60.7	0.98	1.40	3142.2	561.5	525.4	1.07	0.12
	N	18	15	18	18	18	18	18	18	18	18	18	18	18	18
Cerebellum	25%	304.2	3.6	26.6	0.08	11.1	1.7	7.0	0.12	0.46	3095.2	74.2	81.1	0.98	0.08
	50%	326.1	4.5	33.0	0.10	14.3	3.5	10.1	0.22	0.74	3446.4	84.6	92.5	1.08	0.11
	75%	361.3	7.3	41.7	0.13	17.2	5.7	16.1	0.44	1.06	4167.6	100.9	109.3	1.32	0.16
	N	18	15	18	18	18	18	17	17	18	18	18	18	18	18
Olfactory bulb	25%	252.7	6.1	32.7	0.10	200.6	68.7	142.6	0.32	0.62	3249.7	237.4	119.7	0.41	1.09
	50%	289.7	6.5	36.1	0.12	233.9	96.9	175.2	0.38	0.74	3472.2	265.7	130.2	0.44	1.38
	75%	340.9	9.6	45.2	0.16	298.5	114.5	221.0	0.43	0.83	4051.3	320.6	142.0	0.54	1.67
	N	17	9	17	17	17	17	17	17	17	17	17	17	17	17

Monoamines, metabolites and ratios are expressed as median (50%) with the interquartile range (25%-75%). The number of samples in which a specific compound was detected is provided as well. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline.

Table S3: Aged Ts65Dn mice		(nor)adrenergic system				dopaminergic system				serotonergic system				
		NA (ng/ml)	A (ng/ml)	MHPG (ng/ml)	MHPG: NA	DA (ng/ml)	DOPAC (ng/ml)	HVA (ng/ml)	DOPAC: DA	HVA: DA	TRP (ng/ml)	5-HT (ng/ml)	5-HIAA (ng/ml)	5HIAA: 5HT
Frontal cortex	25%	378.2	3.3	61.3	0.13	26.1	14.2	35.5	0.49	0.79	2873.5	439.4	146.1	0.23
	50%	430.8	8.9	63.6	0.14	32.5	18.0	54.7	0.61	1.72	3321.3	546.3	160.8	0.32
	75%	468.5	15.0	70.6	0.19	46.9	29.9	89.7	0.83	2.10	3502.6	607.0	184.2	0.42
	N	11	11	11	11	11	11	11	11	11	11	11	11	11
Temporal cortex	25%	332.3	13.7	71.2	0.17	114.7	69.3	87.9	0.31	0.50	3311.1	440.8	216.2	0.43
	50%	356.2	16.2	87.8	0.20	180.7	79.3	114.2	0.46	0.62	3928.2	539.7	231.5	0.46
	75%	488.6	30.8	93.9	0.27	265.3	108.2	143.7	0.69	1.08	4907.5	575.5	281.1	0.53
	N	11	5	11	11	11	11	11	11	11	11	11	11	11
Parietal cortex	25%	460.7	6.4	44.2	0.08	20.2	5.2	9.2	0.19	0.47	3249.9	268.4	145.8	0.36
	50%	548.5	11.7	59.2	0.10	27.4	9.1	15.5	0.26	0.55	3412.1	341.1	170.6	0.51
	75%	628.3	12.4	79.9	0.14	41.5	12.3	27.4	0.46	1.06	3794.5	399.4	210.5	0.70
	N	11	7	11	11	11	11	11	11	11	11	11	11	11
Occipital cortex	25%	275.3	0.5	22.8	0.08	13.9	4.1	3.1	0.06	0.13	3219.0	180.7	113.8	0.56
	50%	354.1	8.8	43.3	0.12	36.9	5.3	9.2	0.13	0.19	3336.6	204.9	127.6	0.62
	75%	434.8	14.7	57.4	0.14	101.7	7.1	10.8	0.32	0.29	3829.7	238.3	167.8	0.68
	N	11	9	11	11	11	11	7	11	7	11	11	11	7
Hippocampus	25%	359.6	2.2	31.8	0.09	29.1	17.3	31.5	0.39	0.92	3117.5	435.4	373.5	0.71
	50%	409.6	3.4	45.5	0.12	38.2	21.0	39.6	0.53	1.06	3326.0	528.7	434.2	0.86
	75%	451.8	5.8	62.8	0.16	44.0	26.3	45.1	0.66	1.27	3855.0	574.9	480.0	0.93
	N	11	11	11	11	11	11	11	11	11	11	11	11	11
Striatum	25%	130.2	6.1	35.5	0.17	7139.0	731.3	908.8	0.09	0.10	3362.3	385.9	282.7	0.64
	50%	183.9	12.5	41.3	0.24	8142.8	853.4	1114.1	0.10	0.12	3378.7	430.3	303.1	0.75
	75%	220.3	19.4	45.9	0.27	11305.9	1120.9	1126.1	0.12	0.14	3746.8	543.2	369.3	0.82
	N	11	7	11	11	11	11	11	11	11	11	11	11	11
(Hypo)thalamus	25%	582.7	1.6	70.7	0.07	186.1	81.4	154.6	0.36	0.58	3382.9	530.0	466.6	0.77
	50%	766.4	3.3	80.0	0.10	232.1	116.3	172.2	0.51	0.76	3485.3	595.3	527.1	0.88
	75%	920.3	4.2	86.0	0.15	315.8	146.7	216.0	0.65	0.91	4201.7	749.9	617.8	0.92
	N	11	11	11	11	11	11	11	11	11	11	11	11	11
Brainstem	25%	537.9	1.6	69.8	0.13	34.2	27.8	46.3	0.75	1.11	2519.3	432.9	438.1	0.90
	50%	550.0	2.2	71.1	0.15	41.6	35.3	47.1	0.88	1.30	2635.2	484.9	464.4	0.98
	75%	584.6	2.5	85.5	0.16	44.1	41.6	56.7	0.97	1.43	2963.2	512.8	525.1	1.20
	N	11	7	11	11	11	11	11	11	11	11	11	11	11
Cerebellum	25%	244.7	2.4	15.3	0.06	11.0	9.5	9.3	0.79	0.81	3420.5	82.5	98.4	0.76
	50%	293.8	3.5	22.1	0.07	12.0	11.9	10.9	0.96	1.07	3554.8	106.4	123.0	1.13
	75%	367.8	10.4	42.1	0.10	13.8	14.6	16.5	1.18	1.17	3739.1	146.8	138.5	1.55
	N	11	11	11	11	11	11	11	11	11	11	11	11	11
Olfactory bulb	25%	241.3	5.3	53.2	0.19	164.4	83.6	153.2	0.46	0.78	3476.4	293.3	132.0	0.43
	50%	282.6	7.2	62.8	0.20	223.0	113.3	192.9	0.51	0.89	4535.9	346.8	162.2	0.47
	75%	324.8	10.6	71.8	0.30	245.5	132.3	205.3	0.64	0.93	5485.3	378.6	202.7	0.58
	N	11	6	11	11	11	11	11	11	11	11	11	11	11

Monoamines, metabolites and ratios are expressed as median (50%) with the interquartile range (25%-75%). The number of samples in which a specific compound was detected is provided as well. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline.

Table S4: Aged WT _{Ts50n} mice		(nor)adrenergic system				dopaminergic system				serotonergic system				
		NA (ng/ml)	A (ng/ml)	MHPG (ng/ml)	MHPG: NA	DA (ng/ml)	DOPAC (ng/ml)	HVA (ng/ml)	DOPAC: DA	HVA: DA	TRP (ng/ml)	5-HT (ng/ml)	5-HIAA (ng/ml)	HVA: 5HIAA
Frontal cortex	25%	408.3	1.1	73.7	0.17	20.5	19.3	55.1	0.82	2.21	3152.2	437.6	164.7	0.30
	50%	435.9	2.9	78.9	0.19	24.9	26.5	66.5	0.94	2.43	3464.6	485.3	179.6	0.36
	75%	446.7	8.6	85.4	0.20	40.7	33.5	79.1	1.14	2.84	3776.6	544.4	189.2	0.42
	N	10	10	10	10	10	10	10	10	10	10	10	10	10
Temporal cortex	25%	335.1	-	84.1	0.23	128.5	52.9	56.3	0.26	0.23	4676.7	489.2	258.5	0.43
	50%	357.5	-	92.4	0.26	225.4	75.3	82.8	0.35	0.30	5354.4	611.2	289.6	0.45
	75%	386.7	-	95.7	0.27	436.9	146.8	115.7	0.47	0.43	6314.0	701.1	306.8	0.52
	N	10	0	10	10	10	10	10	10	10	10	10	10	10
Parietal cortex	25%	489.7	9.6	39.1	0.08	18.4	13.5	21.9	0.48	0.76	3228.0	253.5	135.6	0.47
	50%	540.3	10.2	42.8	0.08	29.3	17.5	28.4	0.60	1.08	3543.6	298.4	167.5	0.53
	75%	557.5	12.6	47.1	0.09	34.4	20.1	40.7	0.81	1.46	3898.5	333.5	194.5	0.72
	N	10	10	10	10	10	10	10	10	10	10	10	10	10
Occipital cortex	25%	292.5	0.7	27.7	0.08	12.1	2.4	0.5	0.18	0.02	3217.2	154.1	102.4	0.57
	50%	334.0	1.1	30.7	0.10	15.8	3.5	0.9	0.21	0.07	3456.4	188.3	124.8	0.64
	75%	398.3	1.6	38.6	0.11	27.5	9.1	4.2	0.33	0.25	3698.5	228.2	175.7	0.90
	N	10	8	10	10	10	10	9	10	9	10	10	10	9
Hippocampus	25%	435.4	3.1	43.2	0.09	43.2	22.1	39.1	0.37	0.67	3452.0	470.4	444.1	0.87
	50%	454.8	4.1	56.7	0.13	51.7	34.1	51.7	0.55	0.87	3582.8	525.4	495.6	0.92
	75%	503.4	5.8	62.6	0.14	83.6	39.2	57.7	0.62	1.04	4011.8	636.4	542.1	0.99
	N	10	9	10	10	10	10	10	10	10	10	10	10	10
Striatum	25%	164.8	1.4	36.5	0.16	7656.5	769.3	855.2	0.10	0.11	3529.6	448.9	282.0	0.58
	50%	217.6	3.3	39.5	0.22	8461.0	879.9	897.7	0.11	0.11	3672.4	469.9	302.6	0.63
	75%	241.7	-	46.1	0.25	8961.6	1094.5	1075.6	0.12	0.13	3905.0	532.1	333.4	0.71
	N	10	3	10	10	10	10	10	10	10	10	10	10	10
(Hypo)thalamus	25%	709.5	2.4	75.1	0.09	197.2	102.7	160.9	0.43	0.60	3497.3	592.8	483.7	0.72
	50%	828.3	3.3	79.8	0.10	263.0	120.6	175.5	0.48	0.63	3847.1	645.0	536.3	0.82
	75%	974.3	5.8	99.7	0.11	320.2	168.9	190.4	0.54	0.86	4291.5	736.0	606.0	0.91
	N	10	10	10	10	10	10	10	10	10	10	10	10	10
Brainstem	25%	500.2	1.3	77.4	0.14	37.4	35.1	40.5	0.85	0.95	2822.9	430.3	444.8	0.90
	50%	567.3	1.5	83.4	0.15	39.8	41.1	44.1	0.97	1.14	3041.9	447.6	480.2	0.97
	75%	609.9	-	95.0	0.17	46.2	45.3	48.8	1.14	1.30	3091.8	519.1	504.5	1.13
	N	10	3	10	10	10	10	10	10	10	10	10	10	10
Cerebellum	25%	250.4	2.0	13.5	0.04	10.2	14.1	12.9	1.11	1.07	3412.0	72.4	121.8	1.32
	50%	332.4	4.4	19.3	0.06	12.3	15.2	14.1	1.31	1.20	3774.6	92.0	131.7	1.46
	75%	435.8	8.7	27.7	0.09	15.1	19.0	16.3	1.49	1.34	3994.3	108.2	146.0	1.82
	N	10	9	10	10	10	10	10	10	10	10	10	10	10
Olfactory bulb	25%	253.8	1.2	66.0	0.21	237.8	108.4	187.0	0.44	0.72	4380.1	265.3	114.7	0.39
	50%	301.9	4.4	74.1	0.25	270.2	136.0	222.1	0.52	0.80	5654.0	293.7	132.7	0.44
	75%	340.2	-	82.1	0.31	309.4	163.4	250.8	0.57	0.89	6278.5	307.4	140.6	0.48
	N	10	2	10	10	10	10	10	10	10	10	10	10	10

Monoamines, metabolites and ratios are expressed as median (50%) with the interquartile range (25%-75%). The number of samples in which a specific compound was detected is provided as well. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline.

Table S5: Young Dp1Tyb mice			(nor)adrenergic system			dopaminergic system				serotonergic system				
		NA (ng/ml)	A (ng/ml)	MHPG (ng/ml)	MHPG: NA	DA (ng/ml)	DOPAC (ng/ml)	HVA (ng/ml)	DOPAC: DA	HVA: DA	TRP (ng/ml)	5-HT (ng/ml)	5-HIAA (ng/ml)	HVA: 5HIAA
Frontal cortex	25%	571.1	10.3	75.4	0.12	40.9	21.0	72.3	0.37	1.43	3463.8	383.4	159.0	0.36
	50%	603.3	19.0	88.0	0.15	48.1	23.3	98.1	0.53	1.93	5395.8	465.3	200.1	0.40
	75%	643.7	28.9	102.7	0.18	56.8	25.6	112.1	0.61	2.32	5987.7	539.3	221.4	0.44
	N	g	g	g	g	g	g	g	g	g	g	g	g	g
Temporal cortex	25%	460.5	12.6	104.2	0.19	82.0	42.1	104.1	0.24	0.55	3901.6	356.7	223.2	0.49
	50%	499.8	34.2	116.3	0.22	175.1	54.7	168.0	0.28	0.70	5958.3	417.7	240.2	0.57
	75%	527.4	43.9	175.8	0.40	493.9	120.2	293.7	0.68	1.59	6539.4	503.6	315.1	0.71
	N	g	g	g	g	g	g	g	g	g	g	g	g	g
Parietal cortex	25%	666.2	13.5	86.5	0.12	38.6	11.8	48.1	0.44	1.43	3900.0	363.5	198.1	0.49
	50%	681.3	15.6	93.0	0.14	42.4	73.3	73.3	0.56	1.75	6186.7	451.6	232.4	0.54
	75%	736.1	23.0	106.7	0.16	46.0	25.5	87.2	0.58	1.93	7277.5	473.6	255.4	0.58
	N	g	g	g	g	g	g	g	g	g	g	g	g	g
Occipital cortex	25%	456.8	9.0	76.2	0.15	13.7	4.6	11.4	0.16	0.46	4129.1	183.5	136.9	0.63
	50%	499.8	10.6	83.2	0.18	22.0	5.7	14.5	0.25	0.56	6074.8	241.2	179.0	0.76
	75%	535.4	14.8	95.9	0.19	33.0	9.7	17.9	0.78	1.49	6940.9	318.0	198.9	0.93
	N	g	g	g	g	g	g	g	g	g	g	g	g	g
Hippocampus	25%	508.5	5.3	42.2	0.08	29.9	18.4	63.5	0.39	1.44	4140.8	438.3	431.0	0.95
	50%	535.3	5.9	50.2	0.09	40.2	20.3	67.7	0.53	1.79	5809.4	484.3	545.7	1.09
	75%	582.1	-	54.3	0.10	47.3	25.5	88.0	0.79	2.46	7194.7	521.7	728.6	1.41
	N	g	2	g	g	g	g	g	g	g	g	g	g	g
Striatum	25%	139.3	4.0	65.8	0.32	9568.7	1236.7	1618.5	0.12	0.14	5451.1	318.6	410.5	1.07
	50%	160.1	8.8	72.0	0.40	11226.2	1368.8	1826.5	0.13	0.17	7079.9	348.4	500.4	1.30
	75%	230.4	13.1	78.4	0.54	11743.3	1707.5	2022.2	0.16	0.19	7478.4	408.4	553.4	1.51
	N	g	7	g	g	g	g	g	g	g	g	g	g	g
(Hypo)thalamus	25%	601.6	2.6	80.0	0.11	77.3	51.9	145.0	0.45	1.20	4163.8	390.9	563.6	1.06
	50%	908.1	6.3	96.3	0.12	161.1	108.6	280.0	0.54	1.48	5928.0	499.3	630.5	1.38
	75%	942.8	17.9	119.5	0.14	276.9	141.2	392.8	0.75	1.94	7186.1	566.9	756.5	1.54
	N	g	g	g	g	g	g	g	g	g	g	g	g	g
Brainstem	25%	593.9	6.7	79.6	0.13	46.0	38.8	102.3	0.64	1.44	3646.2	440.3	696.6	1.42
	50%	623.9	6.7	86.3	0.14	53.3	43.0	109.7	0.81	2.11	5801.1	476.5	869.6	1.81
	75%	730.3	6.7	95.1	0.14	78.2	57.2	156.2	0.92	2.58	6765.1	534.8	1032.2	2.09
	N	g	1	g	g	g	g	g	g	g	g	g	g	g
Cerebellum	25%	431.4	3.2	47.2	0.11	17.5	9.8	19.5	0.50	1.01	4058.1	104.9	127.9	1.04
	50%	447.3	4.3	61.2	0.14	19.1	11.9	27.8	0.61	1.28	6532.5	136.4	182.8	1.24
	75%	491.5	8.1	85.8	0.19	21.4	14.0	31.1	0.71	1.64	7538.0	183.7	210.9	1.50
	N	g	7	g	g	g	g	g	g	g	g	g	g	g
Olfactory bulb	25%	352.1	4.8	42.7	0.12	206.9	66.7	189.4	0.28	0.73	3664.1	326.7	184.4	0.56
	50%	387.2	5.9	53.1	0.13	233.6	78.6	246.6	0.34	1.04	4913.2	341.0	234.6	0.66
	75%	416.7	10.2	60.3	0.14	248.5	95.8	253.0	0.44	1.22	5816.3	397.8	265.6	0.76
	N	g	7	g	g	g	g	g	g	g	g	g	g	g

Monoamines, metabolites and ratios are expressed as median (50%) with the interquartile range (25%-75%). The number of samples in which a specific compound was detected is provided as well. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline.

Table S6: Young WT ^{Dp1Tyb} mice		(nor)adrenergic system				dopaminergic system				serotonergic system					
		NA (ng/ml)	A (ng/ml)	MHPG (ng/ml)	MHPG: NA	DA (ng/ml)	DOPAC (ng/ml)	HVA (ng/ml)	DOPAC: DA	HVA: DA	TRP (ng/ml)	5-HT (ng/ml)	5-HIAA (ng/ml)	5HIAA: 5HT	HVA: 5HIAA
Frontal cortex	25%	516.7	9.9	49.8	0.10	31.4	24.4	78.4	0.38	1.49	2794.3	349.7	157.7	0.38	0.45
	50%	550.9	10.9	70.2	0.15	47.5	29.0	98.7	0.67	2.08	3297.3	410.4	213.7	0.53	0.45
	75% N	593.9	23.5	119.7	0.20	66.1	34.5	111.1	1.01	2.83	6218.7	503.5	247.2	0.61	0.47
Temporal cortex	25%	429.8	12.9	87.4	0.19	103.8	43.5	99.3	0.38	0.58	3043.9	385.0	229.0	0.52	0.38
	50%	462.0	34.1	136.0	0.29	163.4	69.2	144.5	0.41	0.80	3740.2	416.2	242.4	0.58	0.61
	75% N	553.9	43.5	162.3	0.33	239.3	85.9	196.0	0.58	1.57	6075.5	493.1	281.9	0.67	0.78
Parietal cortex	25%	606.0	7.5	69.2	0.11	37.8	12.1	42.4	0.29	1.00	3144.8	334.5	206.4	0.46	0.18
	50%	637.2	16.8	81.3	0.12	42.6	19.3	53.4	0.50	1.36	3830.3	386.2	231.1	0.60	0.23
	75% N	680.8	20.1	91.6	0.14	50.0	29.1	67.6	0.62	1.47	6222.6	446.8	255.7	0.77	0.35
Occipital cortex	25%	416.2	8.6	64.8	0.15	18.5	4.9	9.4	0.09	0.32	3471.6	189.3	152.3	0.61	0.06
	50%	439.4	12.7	80.4	0.17	21.5	6.7	11.7	0.25	0.53	3654.0	224.7	167.6	0.82	0.06
	75% N	461.4	16.3	86.1	0.20	49.5	11.5	15.4	0.50	0.63	5726.3	232.4	188.3	0.99	0.09
Hippocampus	25%	439.6	5.6	40.2	0.09	42.6	16.1	58.6	0.37	1.16	3285.8	457.5	444.2	0.95	0.12
	50%	507.6	5.8	47.8	0.10	52.2	20.8	67.6	0.45	1.39	3558.0	476.1	505.5	1.08	0.13
	75% N	550.0	-	66.9	0.12	57.1	25.0	84.6	0.48	1.61	6394.7	515.9	661.3	1.30	0.14
Striatum	25%	155.4	3.9	55.1	0.27	9799.5	1333.3	1484.3	0.12	0.14	3558.4	404.0	395.2	1.00	3.33
	50%	203.6	8.3	67.5	0.33	10938.3	1476.9	1629.0	0.13	0.15	4089.3	415.0	447.9	1.08	3.63
	75% N	236.7	16.6	78.6	0.42	12737.7	1653.8	2004.5	0.16	0.16	6900.1	433.6	581.4	1.22	3.77
(Hypo)thalamus	25%	924.6	10.2	91.1	0.10	168.6	99.1	248.8	0.49	1.22	3383.0	435.5	575.7	1.23	0.42
	50%	1037.0	12.0	117.6	0.12	200.0	124.6	283.1	0.55	1.50	3763.1	470.5	630.7	1.34	0.46
	75% N	1218.2	22.8	162.9	0.14	327.0	178.1	456.9	0.66	1.59	6177.6	563.6	755.8	1.57	0.62
Brainstem	25%	715.5	3.1	80.0	0.11	42.9	40.5	83.2	0.76	1.48	2668.6	413.2	581.1	1.37	0.13
	50%	798.3	3.1	102.0	0.13	60.4	53.6	117.6	0.88	1.71	2980.6	451.6	737.9	1.59	0.14
	75% N	811.9	3.1	116.9	0.14	75.9	74.1	143.6	1.13	2.17	5288.9	586.7	956.8	1.78	0.16
Cerebellum	25%	383.5	2.7	32.3	0.08	13.5	10.3	15.4	0.62	1.00	3080.8	84.4	112.6	1.25	0.11
	50%	409.2	3.6	47.7	0.12	14.9	11.0	17.8	0.74	1.14	3600.2	104.6	149.9	1.36	0.14
	75% N	443.8	9.8	69.6	0.16	20.4	15.1	20.8	0.87	1.34	6258.8	131.9	156.8	1.61	0.15
Olfactory bulb	25%	304.7	3.3	41.2	0.12	223.8	76.3	216.1	0.31	0.93	3364.9	258.7	178.4	0.63	1.01
	50%	345.6	5.6	53.7	0.15	246.2	83.3	273.1	0.33	1.02	3696.5	269.2	191.9	0.71	1.15
	75% N	402.1	9.0	62.4	0.17	277.7	108.9	287.0	0.39	1.11	7683.2	352.0	265.2	0.75	1.41

Monoamines, metabolites and ratios are expressed as median (50%) with the interquartile range (25%-75%). The number of samples in which a specific compound was detected is provided as well. 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, serotonin; A, adrenaline; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; NA, noradrenaline.

